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The role of GM-CSF/IL-3/IL-5 receptor common β subunit (CBS) in 
Hematopoietic Stem and Progenitor Cell (HSPC) expansion, monocytosis and 
atherosclerosis 
Mi Wang 
Atherosclerosis is caused by the recruitment of monocytes to the subendothelial space where 
they develop into macrophage foam cells and give rise to atherosclerotic plaques. Elevated 
numbers of blood monocytes are strongly associated with coronary heart disease likely because 
increased numbers of monocytes drive their infiltration into atherosclerotic plaques. Studies 
using animal models of atherosclerosis including Apolipo protein E knockout (Apoe
-/-
) mice and 





) mice demonstrated that cellular cholesterol retention leads 
to Hematopoietic Stem and Progenitor Cell (HSPC) expansion that underlies monocytosis and 
neutrophilia, coinciding with increased cell surface expression of the common β subunit of the 
Granulocyte-macrophage colony-stimulating factor (GM-CSF) /Interleukine 3 (IL-3 receptor 
(CBS) in the bone marrow HSPCs and increased GM-CSF production in the spleen. These 
observations suggest that CBS signalling could contribute to atherogenesis by promoting 
myeloid expansion.  
 
To investigate the role of CBS in the cholesterol driven HSPC expansion and monocytosis 




 mice through cross-breeding and transplanted 
Low-density lipoprotein (LDL) receptor knockout (Ldlr
-/-






 mice followed by western type diet (WTD) feeding. To confirm that any 
 
 
potential effect of CBS deficiency is specific to the context of atherosclerosis associated 
monocytosis, we also transplanted Ldlr
-/-
 mice with wild type (WT) or Cbs
-/-
 bone marrow. 




 bone marrow 
transplanted mice had fewer circulating monocytes and neutrophils, accompanied by reduced 
HSPC proliferation in both the bone marrow and the spleen. 
 
The spleen has been identified as an important site for extramedullary production of monocytes 
during atherosclerosis and acute inflammatory responses. To investigate the role of CBS in 
extramedullary monocytosis during atherogenesis, we compared WT and Apoe
-/-
 mice fed on a 
WTD and found increased GM-CSF-producing Innate Response Activator (IRA) B cells in the 
spleen of Apoe
-/-
 mice, reflecting increased CBS level on IRA B cells and peritoneal B1a cells 
that are precursors of IRA B cells. CBS deficiency dramatically reduced the number and 
proliferative activity of IRA B cells in the spleen, suggesting that CBS mediates enhanced GM-
CSF production in the spleen by promoting IRA B cell expansion. 
  




 bone marrow transplanted mice 
showed similar levels of atherosclerotic lesion compared with Apoe
-/-
 bone marrow transplanted 
ones. A closer examination of the lesions revealed decreased macrophage content but increased 




 bone marrow recipients.  This could be explained by 
decreased dendritic cells (DCs) and Regulatory T cells (Tregs) in the spleen, which are known to 
exert atheroprotective effects through anti-inflammatory cytokines. Another contributing factor 
appeared to be the decreased expression of ABCG1, an ABC transporter that protects against 




Taken together, our findings indicate that CBS plays a critical role in promoting monocytosis 
during atherogenesis by mediating HSPC proliferation in the bone marrow and GM-CSF 
production in the spleen through IRA B cell expansion, and these events likely contribute to 
macrophage accumulation in the atherosclerosis lesions. The effect of CBS on atherogenesis is 
complex since it affects the development of multiple cell types that exert opposing roles during 
atherosclerosis. To further elucidate the relation between CBS, monocytosis and atherosclerosis, 
a cell- specific knock out approach might be informative.   
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Chapter 1: Introduction 
Atherogenesis 
Atherosclerosis is the leading cause of death and disability in the developed world, and promises 
to assume this role in developing countries in the near future (Roger, Go et al. 2012). This 
disease is characterized by an accumulation of lipids and leukocytes in the arterial wall, leading 
to the development of plaques that protrude into the arterial lumen. Although asymptomatic 
during the initial phase of development, this chronic inflammatory process may eventually lead 
to plaque rupture and thrombosis, which obstructs vessels that supply oxygen to the heart and 
brain, resulting in the acute clinical complications of myocardial infarction and stroke, 
respectively. 
Atherosclerosis begins with the retention and modification of apolipoprotein B-containing 
lipoproteins in the subendothelial space of the blood vessels, leading to an inflammatory 
response of the endothelial cells (Williams and Tabas 1995, Lusis 2000, Glass and Witztum 
2001). The activated endothelial cells express proinflammatory adhesion molecules such as P-
selectin, vascular   cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 
(ICAM-1), which allow for the tethering and rolling of monocytes on the endothelium (Gebuhrer, 
Murphy et al. 1995). Beside adhesion molecules, activated endothelial cells also express 
chemoattractants that recruit adhered monocytes into the intima through diapadesis (Mestas and 
Ley 2008). Among these chemoattractants, CCL5 has been shown through both genetic deletion 
and pharmacological inhibition to play a critical role in mediating monocyte entry into the lesion 
(Braunersreuther, Zernecke et al. 2007, Braunersreuther, Steffens et al. 2008). CCL2, on the 
other hand, was shown to mediate both the release of monocytes from the bone marrow into the 





1998, Jia, Serbina et al. 2008, Soehnlein, Drechsler et al. 2013).   Once taking up residence in the 
intima, these monocytes develop into macrophages that ingest modified and aggregated 
lipoproteins via type A scavenger receptor (SRA) and a member of the type B family, CD36 and 
become foam cells (Kunjathoor, Febbraio et al. 2002). (Fig. 1.1) 
 
Figure 1.1   Overview of atherogenesis. ApoB-LPs enter into the intima and undergo various 
modifications. Modified ApoB-LPs incite inflammatory responses of the endothelial cells, which 
in turn produce adhesion molecules and chemokines that induce the recruitment of monocytes 
into the subendothelial space. These monocytes differentiate into macrophages that become foam 
cells upon uptake of modified LPs. Macrophage foam cells sustain and amplify the inflammatory 
response by secreting cytokines and chemokines. This figure was first published in the review 
article by Kathryn Moore and Ira Tabas in Cell with permission from the publisher (Moore, 
Kathryn; Tabas, Ira.  2011). 





Once ingested, the cholesteryl esters of the lipoproteins are hydrolyzed in late endosomes to 
cholesterol, often referred to as free cholesterol, and fatty acids (Maxfield and Tabas 2005). 
Excessive amount of free cholesterol (FC) induce inflammatory signals and toxicity in 
macrophages, and importantly, late endosomal free cholesterol regulates the free cholesterol 
content in the macrophages through several feedback mechanisms. First, some of the FC is re-
esterified by the ER enzyme acyl-CoA:cholesterol ester transferase (ACAT) into cholesteryl 
fatty acid esters, which constitute the “foam” of foam cells (Brown, Ho et al. 1980). Second, free 
cholesterol can be trafficked to the endoplasmic reticulum (ER) where it downregulates both 
LDL receptors and endogenous cholesterol synthesis by suppressing the sterol-regulatory 
element binding pathway (SREBP) (Brown and Goldstein 1997). Finally, free cholesterol 
released fromo the ER can also traffic to the plasma membrane and thus be available for efflux 
out of the cell, a key process in “reverse cholesterol transport” that leads to plaque regression 
when hypercholesterolemia is reversed. An increase in FC and oxygenated derivatives 
activate  liver X receptor (LXR), which increases transcription of multiple genes involved in 
cholesterol efflux, including Abca1, Abcg1, phospholipid transfer protein, and Apoe (Chawla, 
Repa et al. 2001, Tall, Yvan-Charvet et al. 2008)  
ATP-binding cassette (ABC) transporters, ABCA1 and ABCG1, are thought to be critical during 
this process given their role in mediating transport of cell membrane cholesterol to 
apolipoprotein A1 (ApoA-I) and HDL, respectively. Indeed, mice transplanted with bone 
marrow cells deficient in ABCA1 and ABCG1 showed impaired cholesterol efflux to HDL and 
ApoA-I and accelerated atherosclerosis when fed a high-cholesterol diet (Yvan-Charvet, 
Ranalletta et al. 2007). Clinical studies have further established the atheroprotective effect of 





predictor of cardiovascular events (Gordon, Castelli et al. 1977, Barter, Gotto et al. 2007). 
Genetic defect in ABCA1 causes Tangier disease, where patients suffer from extremely low 
HDL-cholesterol levels, hepatosplenomegaly, peripheral neuropathy and frequently premature 
coronary artery disease (CAD) (Bodzioch, Orsó et al. 1999, Rust, Rosier et al. 1999). Given the 
established role of HDL in mediating cholesterol efflux, it is no surprise that therapeutic 
strategies aimed at raising HDL level and enhancing cholesterol efflux are being actively 
pursued as a potential treatment of atherosclerosis. 
Accumulation of free cholesterol due to ingestion of lipoproteins and/or defective cholesterol 
efflux profoundly alters the function of macrophages. Studies have suggested that enrichment of 
free cholesterol in the plasma membrane enhances the release of inflammatory cytokines 
possibly through increased cholesterol-enriched lipid rafts in the cell membranes (Yvan-Charvet, 
Welch et al. 2008).  In response to LPS stimulation, macrophage-specific knockout of Abca1 
resulted in enhanced expression of cytokines including  tumor  necrosis factor α (TNF-α), 
interleukin 1 β (IL-1 β) and monocyte chemotactic protein-1 (MCP-1) through the activation of 
nuclear factor κ-light-chain-enhancer of activated B cells (NF-κb) and mitogen-activated protein 
kinase (MAPK) pathways in a myeloid differentiation factor 88 (MyD88)-dependent manner, 
and removal of membrane cholesterol via cyclodextrin treatment normalized the difference 
between Abca1
-/-
 and WT macrophages (Koseki, Hirano et al. 2007, Zhu, Lee et al. 2008). 
Similarly, combined deficiency of ABCA1 and ABCG1 led to increased secretion of 
macrophage inflammatory protein-1α (MIP-1 α), MCP-1, CCL-5, IL-6, and IL-1 β, and this is 
associated with enhanced NF-κB and MAPK signaling and increased lipid raft formation in the 
cell membrane (Yvan-Charvet, Ranalletta et al. 2007). MyD88 signaling is believed to mediate 









 mice (Mullick, Tobias et al. 2005). Similarly, TLR4 or 
MyD88 deficiency is associated with reduced lesions size and macrophage infiltration in Apoe
-/-
 
mice (Michelsen, Wong et al. 2004).   
The monocyte-derived macrophage as the protagonist during atherogenesis 
Macrophage foam cells contribute to early atherosclerotic lesions through enhanced 
inflammatory signaling and recruitment of monocytes. Prolonged cholesterol accumulation can 
also lead to apoptosis of macrophage foam cells (Yvan-Charvet, Ranalletta et al. 2007). 
Increasing evidence has established that macrophage dysfunction due to cholesterol imbalance 
contributes to early and advanced atherosclerotic lesions in different ways (Seimon and Tabas 
2009). Macrophage death in early lesions was effectively contained through efferocytic 
clearance, however, in advanced lesions where effereocytosis is impaired, apoptotic 
macrophages contribute to the formation of dangerous plaques containing necrotic core, a key 
process that eventually lead to destabilization and rupture of atherosclerotic lesions. Apoptotic 
cells that fail to be engulfed by efferocytes eventually begin to release their cellular content and 
induce secondary necrosis of neighboring cells, and death of these macrophages  does not reduce 
lesion size but instead leave behind their lipid content, resulting in a lipid laden necrotic core 
(Gautier, Huby et al. 2009).  
Several lines of evidence highlight the importance of monocyte derived macrophages in the 
development of atherosclerosis lesions. First, removal or reduction of monocytes resulted in a 
decrease of atherosclerosis burden. Depletion of circulating monocytes with clodronate resulted 
in a dramatic reduction of atherosclerotic lesion in high-cholesterol diet fed rabbits (Ylitalo, 
Kalliovalkama et al. 1998). Acute reduction of monocytes resulted in an arrest of atherosclerotic 
plaque development in an Apoe
-/-





apparent (Stoneman, Braganza et al. 2007). A loss-of-function mutation in the macrophage 
colony stimulating factor (M-CSF) gene resulted in decreased blood monocytes and significantly 
smaller proximal aortic lesions in Apoe
-/-
 mice (Smith, Trogan et al. 1995). A recent study found 
that Apoe
-/-
 mice lacking classical Ly6C
hi
 monocytes displayed reduced lesion size and lesional 
macrophage content (Soehnlein, Drechsler et al. 2013). Ly6C
hi
 monocytes are known to express 
higher levels of C-C chemokine receptor type 2 (CCR2) and therefore more readily enter 
atherosclerotic lesions than Ly6Clo monocytes.  
Second, blockade of chemokines that mediate monocyte entry into the subendothelial space 
dramatically reduced the progression of atherosclerosis (Combadière, Potteaux et al. 2008, 
Mestas and Ley 2008). Genetic deletions of CCR2, the receptor for MCP-1(CCL2) decreased 
macrophage foam cell formation and atherosclerotic lesion size in Apoe
-/-
 mice (Boring, Gosling 
et al. 1998). Similarly, deletion of CX3CR1, the receptor for fractalkine (CX3CL1), in Apoe
-/-
 
mice resulted in a significant reduction in macrophage recruitment to the intima and decreased 
atherosclerotic lesion formation (Combadière, Potteaux et al. 2003, Lesnik, Haskell et al. 2003). 
Combined deficiency of CCR2 and CX3CR1 achieved even greater reduction of atherosclerosis 
lesions in Apoe
-/-
 mice (Saederup, Chan et al. 2008).   
Clinical evidence linking monocytosis and atherosclerosis 
Given the crucial role of monocyte derived macrophages in atherogenesis, it is perhaps not 
surprising that the number of blood monocytes is correlated with the extent of the disease. It has 
been reported that total leukocyte count measured 16.8 months beforehand was positively 
correlated with myocardial infarction (Friedman, Klatsky et al. 1974). Subsequent clinical 





prospective studies (Sweetnam, Thomas et al. 1997, Lee, Folsom et al. 2001, Coller 2005). In the 
Caerphilly and Speedwell studies of 4,860 men between 45-63 years old, a 10-year follow-up 
revealed that total leukocyte count predicted ischemic heart disease events independent of other 
risk factors. The neutrophil count was identified to be a main risk factor (Sweetnam, Thomas et 
al. 1997). Another 8-year follow-up study found a direct association between white blood cell 
count and incidence of coronary heart disease, stroke and mortality from cardiovascular disease 
in both African Americans and Whites (Gillum, Mussolino et al. 1997).  
In addition to these studies that link leukocyte counts with cardiovascular diseases, monocyte 
count, in particular, was found to independently predict cardiovascular diseases.  In the Paris 
Prospective Study II with 3,779 French male, high levels of monocytes predicted risk of 
coronary heart disease after adjustment for classical risk factors (Olivares, Ducimetière et al. 
1993). More recently, the monocyte count was also found to independently predict the risk for 
carotid plaque burden following adjustment for conventional risk factors (Chapman, Beilby et al. 
2004). Moreover, a recent study identified an association between mild renal dysfunction and an 
increase in circulating monocytes. Renal dysfunction has been linked with increased 
cardiovascular risk, although the mechanism is unclear. In this study, monocytes were found to 
be independently associated with carotid bulb intima-media thickness (Ganda, Magnusson et al. 
2013). Furthermore, in patients receiving statin treatment, an improved lipoprotein profile – 
increased HDL and decreased LDL levels- was associated with decreased monocyte counts (Tani, 
Nagao et al. 2009).  
Studies in Animal models that link monocytosis and atherosclerosis 
Monocytosis and neutrophilia have also been observed in animal models of atherosclerosis 





al. 1989, Feldman, Mogelesky et al. 1991) In these models, the animals were fed a high-
cholesterol diet and developed monocytosis, and this was reversed once the animals were 
switched back to a chow diet. The increase in monocyte count was associated with greater 
cellularity and cell proliferation activity in the bone marrow and increased colony forming 
capacity of the bone marrow cells.  
Hypercholesterolemia-induced monocytosis has also been documented in mouse models of 
atherosclerosis. Western type diet (WTD)-fed Apoe
-/-
 mice developed a dramatic increase in the 
Ly-6C
hi
 monocyte subset (Swirski, Libby et al. 2007, Tacke, Alvarez et al. 2007). 
Hypercholesterolemia-induced neutrophilia has also been reported to contribute to early 
atherosclerotic lesion formation in Apoe
-/-
 mice (Drechsler, Megens et al. 2010). Conversely, 
reduction of monocytes in the circulation through interruption of M-CSF or MCP-1 activity 




 mice. (Smith, Trogan et al. 1995, Rajavashisth, 
Qiao et al. 1998) 
In addition to typical hypercholesterolemia atherosclerosis models, an ischemic injury triggered 
advanced atherosclerosis model provided additional insight into the contribution of monocytosis 
to atherosclerosis progression (Dutta, Courties et al. 2012). It has been observed that acute 
coronary syndromes predispose the survivors to a higher risk of recurrent events; similarly, 
myocardial infarction or stroke triggered even larger atherosclerotic lesions in Apoe
-/-
 mice. The 
exacerbation of lesion development was associated with enhance mobilization of HSPCs from 
the bone marrow induced by sympathetic nervous activation. The progenitor cells yielded more 
monocytes through extramedullary myelopoiesis in the spleen, contributing to enhanced 





and increased risk of recurrent evens could be a result of enhanced monocyte production through 
HSPC mobilization and the subsequent extramedullary myelopoiesis. 
Mechanisms of monocytosis during atherogenesis – perspectives from the bone marrow  
In recent years, the mechanisms underlying elevated monocyte levels have been elucidated in 
several studies using mouse models of atherosclerosis. Studies have suggested that HSPC 
proliferation and expansion underlies the monocytosis and neutrophilia observed in these models 
(Soehnlein and Swirski 2012, Tall, Yvan-Charvet et al. 2012). One study employed mice that 
lacked ABCA1 and ABCG1. Double deficiency of ABCA1 and ABCG1 resulted in elevated 
blood leukocyte and monocyte counts in mice consuming a chow diet, and Western Type Diet 
(WTD) feeding exacerbated the fndings. These mice displayed increased numbers and 
proliferation of bone marrow HSPCs, granulocyte-monocyte progenitor (GMP) and the common 
myeloid progenitor (CMP). Ldlr
-/-




 bone marrow 
displayed accelerated atherosclerosis and extensive infiltration of macrophage foam cells 
compared with Ldlr
-/-
 mice transplanted with wild type bone marrow.  After reconstituting Ldlr
-/-
 









 outpaced that 
of the CD45.1 WT bone marrow cells. The observation that CD45.1 WT bone marrow cell 




 cells confirmed a cell 




 bone marrow derived HSPCs. While 





bone marrow derived HSPCs, IL-3 and GM-CSF significantly increased bromodeoxyuridine 




HSPCs and bone marrow cells compared with WT 









HSPCs. Consistent with this notion, the shared common beta subunit (CBS) of 




 HSPCs. This increased cell 
surface level of the CBS correlated with increased cell membrane cholesterol content and 
enhanced Ras/Erk signaling that is down stream of IL-3 and GM-CSF. These findings illustrate a 
mechanism for HSPCs to respond to cholesterol retention in the cell membrane by increasing cell 
surface level of CBS that leads to enhanced myeloid expansion (Yvan-Charvet, Pagler et al. 
2010).  
Interestingly, targeted deletion of ABCA1 and ABCG1 in macrophages alone resulted in similar 
levels of blood monocytes in mice fed with a chow diet compared to controls, and this was 
accompanied by moderately increased atherosclerosis (Westerterp, Murphy et al. 2013). WTD-
fed mice with macrophage –specific deletion of ABCA1 and ABCG1, on the other hand, 
displayed disproportionate atherosclerosis given their relatively low cholesterol levels compared 
to controls, and monocytosis and neutrophilia in the absence of HSPC proliferation. The 
enhanced atherosclerosis could be attributed to the elevated leukocyte levels. The myeloid 
expansion in these mice was found to be cell-extrinsic and mediated by increased M-CSF and G-
CSF expression in splenic macrophages. This uncovers another mechanism of monocytosis 
during atherogenesis, namely the inflammatory cytokine mediated myeloid expansion.  





 mice are two of the most commonly used animal models of atherosclerosis, and 
myeloid expansion was observed in both. Ldlr
-/-
 mice have elevated plasma cholesterol level and 
are prone to dietary cholesterol induced atherosclerosis since LDL receptor mediates cholesterol 
clearance via the liver (Ishibashi, Brown et al. 1993). Apoe
-/-
 mice develop much more severe 





plasma cholesterol as well as remnants of chylomicrons from the intestine (Zhang, Reddick et al. 
1992). Apoe
-/-
 mice developed robust monocytosis and neutrophilia after 10 weeks of WTD 
feeding while Ldlr
-/-





 mice showed significantly elevated monocyte level and enhanced 
HSPC expansion in the bone marrow. Mechanistic studies revealed that ApoE is expressed on 
the surface of HSPC and interacts with ABCA1 and ABCG1 to promote cholesterol efflux and 
suppress HSPC proliferation. Since this mechanism relies on the endogenous ApoE molecules 
instead of the circulating Apoe in the plasma, HSPC expansion and leukocytosis in Apoe
-/-
 mice 
is cell-autonomous. When Ldlr
-/-
 mice were transplanted with equal portion of CD45.1 WT bone 
marrow cells and CD45.2 Apoe
-/-
 bone marrow cells, CD45.2 Apoe
-/-
 monocytes and HSPC 
outpaced their CD45.1 WT counterparts in their proliferation activity, resulting in preferential 







 mice also had elevated cell surface expression of CBS, 
increased cholesterol accumulation and lipid raft formation on the cells membrane and 
hypersensitivity to IL-3/GM-CSF signaling via ERK1/2 and STAT5 (Murphy, Akhtari et al. 






Figure 1.2.  Mechanism of cholesterol-driven increased HPSC expansion mediated by CBS 
signaling. i) Endogenous ApoE acts as a ligand for ABCA1 during cholesterol efflux in HSPCs 
and form ApoE-HDL. ii) These ApoE-HDL particles acts as ligand for ABCG1 mediated 
cholesterol efflux. iii) Cell surface level of CBS is modulated by the cholesterol content, and 
defective cholesterol efflux leads to increased cellular level of CBS and hypersensitivity to IL-
3/GM-CSF. iv) Enhanced IL-3/GM-CSF signaling leads to increased proliferation of HSPCs, 
myeloid expansion and accelerated atherosclerosis. The illustration was first published in J Clin 
Invest by Andrew Murphy, et al with permission from the publisher. (Murphy, Akhtari et al. 
2011) 
Mechanisms of monocytosis during atherogenesis – perspectives from the spleen  
Besides the cell-autonomous expansion of HSPC correlated with increased cell surface level of 





models. Another study using Apoe
-/-
 mice identified the spleen to be an important site for the 
production of monocytes during atherosclerosis. In a spleen transplantation experiment, spleen 
derived monocytes were found in the atherosclerotic lesion of the recipient mice.  GFP
+
 GMPs 
were adoptively transferred into WTD-fed Apoe
-/-
 mice with or without their spleens. A much 
greater number of GFP
+
 myeloid cells were found in the circulation as well as the aorta of the 
recipient mice with intact spleens, whereas GMPs failed to give rise to monocytes and lesional 
macrophages in splenectomized mice. Flow cytometry analysis revealed that Apoe
-/-
 mice had 
increased number of GM-CSF and IL-3-producing cells in the spleen compared with WT mice, 
and injection of neutralizing antibodies for IL-3 and/or GM-CSF suppressed monocyte 
production and GMP survival in the spleen. These observations collectively underscored the 
importance of extramedullary expansion of HSPCs and myeloid progenitor cells in the spleen 
during atherogenesis (Robbins, Chudnovskiy et al. 2012).  
Although the relevance of GM-CSF and IL-3-producing cells to monocytosis is clear, the 
identity of these cells remained obscure. In the same study, it was reported that LPS stimulation 
promoted the production of these cells in the spleen of Apoe
-/-
 mice. In a subsequent study from 
the same group, LPS injection caused a marked increase in the number of GM-CSF and IL-3 
positive cells in the spleen. Flow cytometry analysis identified these cells to be a unique set of B 
cells that produce GM-CSF and IL-3 in the spleen during inflammation. The authors termed 
them innate response adaptor (IRA) B cells given the established role of GM-CSF in innate 
immunity (Rauch, Chudnovskiy et al. 2012).  
Given the similarities between the IRA B cells and the GM-CSF producing splenic cells in WTD 
fed Apoe
-/-
 mentioned above, it is possible that IRA B cells are at least partially responsible for 





separate mechanism as the effect of these cytokines will be cell-extrinsic whereas the HSPC 
expansion due to increased cell surface CBS level is cell-autonomous, although it should be 
noted that both mechanisms would involve CBS signaling. 
The common β subunit of IL-3/GM-CSF/IL-5 receptor 
CBS (aka CD131) is the beta subunit shared by the receptors of IL-3, GM-CSF, and IL-5. In 
humans, CD131 is encoded by the gene Csf2rb (Bagley, Woodcock et al. 1995). In mice, 
Csf2rb1 encodes the ortholog of CD131, whereas Csf2rb2 encodes a second protein that is 
homologous to CD131 but can only form a functional receptor with the IL-3 α subunit (Itoh, 
Yonehara et al. 1990). This protein product of Csf2rb2 has been termed βIL-3 and likely 
represents a gene duplication. Csf2rb1 and Csf2rb2 share 91% nucleotide identity and are located 
in close proximity on mouse chromosome 15. Due to their partial functional redundancy and the 




 mouse will be used in this study, CBS will be used to denote the 






.   
The CBS plays a central role in hematopoiesis, reflecting the function of GM-CSF, IL-3 and IL-5 
in myeloid lineage development (Bagley, Woodcock et al. 1997, Hercus, Thomas et al. 2009). 
The primary role of these cytokines is believed to be mediating immune responses during 
infections rather than in the steady state production of blood cells (Metcalf 1993). Mice lacking 
CBS developed a progressive accumulation of surfactant lipids and proteins in the alveolar space, 
the defining characteristic of the idiopathic human disorder pulmonary alveolar proteinosis. 
However, their hematopoiesis was largely normal except for the reduced basal levels of 







CBS signaling pathway 
Despite considerable differences in the primary amino acid sequences of GM‐CSF, IL‐3, and IL‐
5, their three‐dimensional structures show remarkable similarity, and are associated with similar 
mechanisms of activation in their receptors on target cells (Murphy and Young 2006). The 
cytoplasmic domains of these receptors lack any catalytic activity (Sakamaki, Miyajima et al. 
1992), but Janus Kinase (JAK) 2 has been found to be constitutively associated with the 
cytoplasmic domain of  both CBS and the alpha subunit. High affinity binding of cytokine 
ligands brings the cytoplasmic domains of the alpha and the CBS into close proximity and 
appropriate orientation so that JAKs are able to transactivate one another and initiate signaling 
(Kouro, Kikuchi et al. 1996). Activated JAK2 phosphorylates several tyrosine domains on CBS 
(Y577, Y612, Y695, Y750, Y806, and Y866), which subsequently serve as docking sites for a 
variety of downstream signaling proteins. Phosphorylation of recruited STATs alters their 
conformation, which allows the formation of homodimers or heterodimers with DNA-binding 
and transcription-regulating ability. These dimers then translocate to the nucleus where they act 
as functional transcription factors. Activation of the MAPK pathway is initiated by recruitment 
of SH-2 containing protein (SHC) to Y577. Recruitment of murine homologue of Drosophila 
Son of Sevenless (mSOS) to the SHC/GRB2 complex enables mSOS to catalyze RAS activation. 
Formation of active GTP-bound RAS from inactive GDP-bound RAS leads to the successive 
activation of RAF, MEK, and Erk. Recruitment and phosphorylation of PI3K leads to its 
activation that in turn generates PtdIns(3,4,5)P3 (PIP3), a second messenger that regulates a large 






Figure 1.3. CBS signaling pathways. Upon ligand engagement, CBS is brought into close 
proximity with the alpha subunit of the receptor, allowing JAK2 associated with each subunit to 
transactivate one another and initiate signaling. Activated JAK2 phosphorylates CBS, providing 
docking site for downstream signaling molecules with phosphorylation-recognition domains. 
Recruitment of these downstream signaling molecules leads to gene transcription via STAT5, 
MAPK or PI3K pathways.  This figure is adapted from an original figure published by P. D. 
Emanuel in Leukemia with permission from the publisher. (Emanuel 2008)  
Function of GM-CSF, IL-3 and IL-5 
GM-CSF 
GM-CSF mediates myeloid lineage specification and specifically the development of monocyte, 
dendritic cells (DCs) and neutrophils. It also regulates certain aspects of macrophage functions 





hematopoiesis but developed pulmonary alveolar proteinosis due to defective clearance of 
surfactant by resident macrophages in the lung (Dranoff, Crawford et al. 1994, Stanley, Lieschke 
et al. 1994, Scott and Begley 1999).  While these studies suggest a lack of requirement of basal 
levels of GM-CSF in hematopoiesis (Williamson, Begley et al. 1988), transgenic mice that 
overproduce GM-CSF showed a dramatic expansion of macrophages that led to tissue damage in 
multiple organs (Lang, Metcalf et al. 1987). Systemic or intraperitoneal GM-CSF injection in 
mice led to enhanced production of circulating neutrophils and peritoneal macrophages (Metcalf, 
Begley et al. 1987). Clinical evidence also points to important functions of GM-CSF as an 
immune stimulator. Increased levels of GM-CSF were found in the affected joint fluid of arthritis 
patients (Williamson, Begley et al. 1988) and at the site of reaction in allergic patients (Kay, 
Ying et al. 1991). GM-CSF also serves as a potent stimulator of adaptive immunity. Vaccination 
with irradiated tumor cells engineered to secrete GM-CSF enhances antitumor immunity in both 
murine models and patients with metastatic melanoma and non-small-cell-lung cancer (Salgia, 
Lynch et al. 2003, Soiffer, Hodi et al. 2003).  
GM-CSF is also known for its role in generating dendritic cells. GM-CSF facilitates the in vitro 
development of dendritic cells from mouse and human hematopoietic progenitors and human 
circulating monocytes (Inaba, Inaba et al. 1992, Sallusto and Lanzavecchia 1994, Caux, 







 DCs and the more heterogeneous CD11b
+ 
DCs. Evidence exists to 
support a role for GM-CSF in the development of both types of DCs. GM-CSF is found to be 
increased in the serum of inflamed mice and likely contributes to the conversion of circulating 
monocytes into tissue CD11b
+










(Bogunovic, Ginhoux et al. 2009, King, Kroenke et al. 2010, Greter, Helft et al. 2012).  
These observations established GM-CSF as an immune response mediator during autoimmune 
diseases and inflammation. However, it should be noted that GM-CSF has also been reported to 
play anti-inflammatory roles, including prevention of atherosclerosis in rabbits by enhancing 
smooth muscle cells apoptosis and decreasing collagen and extracellular lipid deposits in the 
atherosclerotic plaques (Shindo, Ishibashi et al. 1999).  
Functions of IL-3 
IL-3 and GM-CSF are generally perceived to have overlapping and synergistic roles. IL-3 is 
more involved in promoting HSPC survival and proliferation and therefore has a broad spectrum 
of effects on hematopoiesis (Suda, Suda et al. 1985, Metcalf, Begley et al. 1986, Donahue, 
Seehra et al. 1988, Martinez-Moczygemba and Huston 2003). The relative cellular expression of 
IL-3R alpha partially determines the cellular responsiveness of IL-3.  IL-3 promotes basophil and 
mast cell development and expansion during parasite infection, although deletion of the IL-3 did 
not result in altered basal level of these cells (Lantz, Boesiger et al. 1998). It has also been 
reported to act synergistically with TNF-α to promote the development of DCs from 
hematopoietic progenitor cells (Caux, Vanbervliet et al. 1996). IL-3 is noted for its role in 
supporting cell survival as IL-3, but not IL-5 or GM-CSF, prevents basophil apoptosis in vitro 
through the activation of PI3K (Zheng, Karsan et al. 2002).  
Function of IL-5  
IL-5 is more intimately involved in the development of eosinophils and B cells.  After airway 





reactivity, which are hallmarks of asthma and usually occurs after 24 hours of allergen challenge 
(Foster, Hogan et al. 1996).  
IL-5 is also known for inducing the terminal differentiation of activated B cells into 
immunoglobulin-secreting cells through STAT5 activation (Horikawa and Takatsu 2006) and 
plays an important role in maintaining the number, cell size and functions of mature B-1 cells. 
Genetic disruption of IL-5Rα or blockade of IL-5 with a neutralizing antibody resulted in 
reduced number of B1 cells. IL-5
-/- 
mice demonstrated defective B1cell development at 2 weeks 
old (Kopf, Brombacher et al. 1996).  IL-5 stimulation of wild-type B-1 cells, but not IL-5rα−/− B-
1 cells, enhances IgM and IgG production (Moon, Takaki et al. 2004). Similar to IL-3 and GM-
CSF, a lack of IL-5 and eosinophils is not associated with changes of basal level hematopoiesis 
but may increase risk for malignancies during infections (Vallance, Matthaei et al. 2000).  





Figure 1.4. IL-3, GM-CSF and IL-5 play important and sometimes overlapping roles in 
hematopoiesis. GM-CSF mediates myeloid lineage specification and specifically the 
development of monocyte, dendritic cells and neutrophils. IL-3 is involved in promoting HSPC 
survival and proliferation. IL-5 is more intimately involved the in the development of eosinophil 
and B cells. This figure is adapted from an original illustration published in Oncogene by L Robb 
with permission from the publisher (Robb 2007).  
GM-CSF, IL-3 and IL-5 in atherosclerosis 
GM-CSF in atherosclerosis 
Due to their redundant roles in hematopoiesis, deletion of any one of these cytokines failed to 
produce appreciable reduction  of the number of white blood cells in general and monocytes in 









particular. Therefore, past literature on the individual roles of these cytokines in atherosclerosis 
would not help elucidate the role of CBS in monocytosis during atherosclerosis. However, it is 
worth reviewing the individual roles that they each play during atherosclerosis to gain a more 
comprehensive picture of the potential impact of CBS in the development of the disease.  





mice had a dramatic reduction of atherosclerotic lesion size and dendritic cell contents in the 
aortic lesions compared with Ldlr
-/-
 mice (Shaposhnik, Wang et al. 2007). Consistent with these 
observations, injection of GM-CSF markedly increased dendritic cell proliferation in early 
lesions, whereas function-blocking anti–GM-CSF antibody inhibited their proliferation (Zhu, 
Chen et al. 2009). Somewhat paradoxically, in Apoe
-/-
 mice deficient in GM-CSF, atherosclerotic 
lesion size increased, accompanied by increased macrophage accumulation, decreased ABCA1 
expression and increased MCP-1 and TNF-α expression in the lesions (Ditiatkovski, Toh et al. 
2006). This likely reflects the role of GM-CSF in regulating multiple cells types in the setting of 
inflammation as occurs in atherosclerosis, and the complexity of the pathogenesis of 
atherosclerosis due to the various cell types involved. 
IL-3 in atherosclerosis 
IL-3 was found in the T lymphocytes that have infiltrated atherosclerotic plaques. In vitro 
experiments demonstrated that IL-3 stimulates vascular endothelial growth factor (VEGF) gene 
transcription, which might lead to smooth muscle cell migration and proliferation (Brizzi, 
Formato et al. 2001). Furthermore, IL-3 was found to be elevated in patients with cardiovascular 
disease, and high IL-3 levels were found to predict the risk of symptomatic restenosis in patients 
undergoing percutaneous coronary intervention (Rudolph, Schaps et al. 2009).  





IL-5 plays a key role in B1 cell maintenance and B1 a cells are known to produce natural 
atheroprotective IgM antibodies against oxidized LDL which inhibits the uptake of oxLDL by 
macrophages. Thus, IL-5 links adaptive and natural immunity and protects again atherosclerosis. 
Ldlr
-/-
 mice receiving bone marrow from Il-5
-/- 
mice demonstrated accelerated atherosclerosis and 
decreased titers of atheroprotective IgMs (Binder, Hartvigsen et al. 2004, Ait-Oufella, Taleb et al. 
2011).  
Other cells types in atherosclerosis and their potential links to CBS 
Neutrophils in atherosclerosis 






 mice fed on WTD, neutrophilia 
accompanied monocytosis. Although neutrophils have received less attention than monocytes 
and macrophages in the study of atherosclerosis in the past, they have been reported to promote 
early atherosclerosis development (Drechsler, Megens et al. 2010), and the mechanism seems to 
involve the fact that OxLDL induce neutrophil to release inflammatory cytokines that sustain 
monocyte recruitment (Soehnlein and Lindbom 2010). During typical inflammation responses, 
the accumulation of neutrophil precedes the recruitment of monocytes. This led to the suggestion 
that neutrophils might play a role in mediating monocyte response. Recent studies revealed that 
neutrophil-derived cathelicidins (CRAMP) induce the adhesion of monocytes by facilitating the 
interaction of monocyte integrins and VCAM-1 and ICAM-1 (Swirski and Robbins 2013). The 
relevance of this mechanism to atherosclerosis is confirmed by the observation that CRAMP 
deficiency led to reduced atherosclerotic lesions and macrophage contents in Apoe
-/-
 mice 





Considering that GM-CSF, IL-3and IL-5 are all involved in the development of neutrophils, it is 
important to monitor neutrophil development when evaluating the consequence of CBS 
deficiency on the development of atherosclerosis. 
B cells in atherosclerosis 
As mentioned before, B1a B cells-derived IRA B cells protect the hosts from polymicrobial 
sepsis through their production of GM-CSF in the spleen and could contribute to atherosclerosis 
by promoting extramedullary monocyte expansion (Rauch, Chudnovskiy et al. 2012). On the 
other hand, B1a cells exert an atheroprotective role by producing IgMs that neutralize OxLDL. 
Efforts to dissect the role of different subtypes of B cells in atherosclerosis have produced a 
complex picture (Perry, Bender et al. 2012). Removal of B cells through splenectomy in Apoe
-/-
 
mice resulted in exacerbated atherosclerosis compared to the sham operated Apoe
-/-
 mice, and 
adoptive transfer of splenic B cells from Apoe
-/-
 mice not only rescued these mice from the 
atherogenic effects of splenectomy but also further reduced atherosclerotic lesions compared 
with the sham operated animals, suggesting that the spleen contains atheroprotective B cell 
population as well as atherogenic cell populations (Caligiuri, Nicoletti et al. 2002). Consistent 
with these findings, adoptive transfer of splenic B cells from Apoe
−/−
 mice into B cell deficient 
μMT Apoe−/− mice also reduced WTD-induced atherosclerosis (Doran, Lipinski et al. 2012). 
Similarly, Ldlr
-/-
 mice receiving bone marrow transplantation from µMT mice demonstrated 
enhanced atherosclerosis compared with WT bone marrow transplanted Ldlr
-/-
 mice (Major, 
Fazio et al. 2002).  
These observations are consistent with the finding that the ability to secret IgM is essential to the 
atheroprotective effect of B cells in Ldlr
-/-
 mice (Lewis, Malik et al. 2009). Studies from 





and blocks the uptake of oxLDL by macrophages in response to IL-5 stimulation (Binder, 
Hartvigsen et al. 2004). This is further confirmed by the observation that adoptive transfer of B1 
a cells from mice lacking IgM producing ability failed to ameliorate splenectomy-aggravated 
atherosclerotic lesions (Kyaw, Tay et al. 2011).  
However, evidence has also emerged to support an atherogenic role for B cells. Depletion of B 
cells in Apoe
-/-
 mice with anti-CD20 monoclonal antibody reduced atherosclerosis in Apoe-/- 
mice fed a WTD in two independent studies (Ait-Oufella, Herbin et al. 2010, Kyaw, Tay et al. 
2010). Specific depletion of B2 cells through genetic disruption of BAFFR, a molecule that is 
essential for the survival of B2 cells, resulted in reduced atherosclerosis in Apoe
-/-
 mice (Kyaw, 
Tay et al. 2012).  Baffr
-/-
 bone marrow transplanted Ldlr
-/-
 mice also had less atherosclerosis 
compared with WT bone marrow transplanted ones (Sage, Tsiantoulas et al. 2012).  
These studies established a significant role for B cells in atherosclerosis, although their specific 
contribution, either being atheroprotective or atherogenic, depends on the particular subtypes of 
B cells that are examined. And given the role of IL-5 in B cell development, we must take it into 
consideration when examining the effect of CBS deficiency on atherosclerosis development. 
Dendritic cells in atherosclerosis 
As mentioned above, GM-CSF plays a key role in the development and augmentation of 
dendritic cell population during inflammation. Given the heterogeneity within the dendritic cell 
population (Hashimoto, Miller et al. 2011), the impact of dendritic cells on atherosclerosis 
development is also dependent on the subtypes of these cells.  













 classical DCs. Both types of DCs were found to expand during atherosclerosis. During 
atherogenesis, DCs take up atherosclerosis-specific antigens followed by migration to adjacent 
lymph nodes, where they present the antigen to naïve T cells, leading to T cell activation and 
proliferation. Inhibition of the antigen presentation process leads to reduced atherosclerosis 
(Hermansson, Ketelhuth et al. 2010).  TLR activation is known to trigger antigen presentation as 
well as production of atherogenic cytokines and chemokines such as TNF, IL-12 and CCL2 
(Koltsova and Ley 2011). These observations would suggest an atherogenic role for DCs.  





 classical DCs in Ldlr
-/-





resulted in exacerbated atherosclerosis, decreased Foxp3
+
 Regulatory T cells (Tregs) in the 
spleen, lymph nodes as well as atherosclerotic lesions, and increased inflammatory cytokine 
mRNAs in the aorta (Choi, Cheong et al. 2011).  Tregs are T lymphocytes that are involved in 
the induction of systemic immune tolerance and play an anti-inflammatory role. In 
atherosclerosis, Tregs have been shown to limit activation of DCs using surface molecules such 
as CTL-associated protein 4 (CTLA-4), secret anti-inflammatory cytokines such as IL-10, IL-35 
and TGF-β, and dampen T-cell proliferation and proinflammatory cytokine production (Lahoute, 
Herbin et al. 2011). Another study employed Ldlr
-/-
 mice transplanted with bone marrow from 
CD11c
+
 DC-specific MYD88 knockout mice which lack TLR activation and found a dramatic 
reduction of both activated effector T cells and Tregs in the atherosclerotic lesions. Although the 
lack of activated effector T cells would supposedly decrease atherosclerosis, this lack of TLR 
activation of DCs on balance resulted in increased atherosclerotic lesions, reflecting increased 
monocyte infiltration due to increased MCP-1 in the lesions, suggesting a predominantly 





Given the role of CBS in mediating GM-CSF signaling and the crucial role of GM-CSF in DC 
development, it is possible that CBS could impact atherosclerosis through altered DC 
populations. 
Hypothesis and study design 
Given the evidence presented above, we hypothesize that 1) CBS plays an important role in 
promoting monocytosis through HSPC expansion in the bone marrow and the spleen, 2) CBS 
promotes extramedullary myelopoiesis by mediating the development of IRA B cell and the 
production of GM-CSF and IL-3 in the spleen, and 3) CBS-mediated HSPC expansion and 
monocytosis play an important role in atherogenesis. 






 bone marrow into irradiated 
Ldlr
-/- 
mice, and examined the effect of CBS deficiency on circulating monocyte level and HSPC 
proliferation in the bone marrow and the spleen.  
With regard to hypothesis 2), we compared WTD-fed WT and Apoe
-/-
 mice for their IRA B cell 
levels and explored the CBS expression level in these cells.  To confirm a role for CBS in 
promoting IRA B cells development, we compared IRA B cell counts and proliferation activity 
in the spleen of the Ldlr
-/- 






 bone marrow.  
To test hypothesis 3), we used the aforementioned bone marrow transplant models to examine 
the impact of CBS deficiency on atherosclerotic lesion size, cell content and the functions of 






Chapter 2: CBS plays an important role in mediating monocytosis during atherogenesis by 
promoting HSPC expansion in the bone marrow and the spleen 
Introduction 
The aim of this study is to assess the role of CBS specifically in monocytosis and HSPC 
expansion associated with atherogenesis. Therefore, it is important that we choose an 
atherosclerosis model with a robust monocytosis phenotype. Among the most commonly used 
mouse models of atherosclerosis, both Apoe
-/-




mice show elevated 
number of monocytes after WTD feeding.   Previous studies in our laboratory have established 
that Apoe
-/- 
mice display significant monocytosis after 4 weeks of WTD feeding, and the 
monocyte levels continue to rise after 8 weeks of WTD. Ldlr
-/- 
mice, another common model for 
atherosclerosis did not develop an appreciable degree of monocytosis after 10 weeks of WTD, 







 mice are considerably superior breeders. Given these 
considerations, we decided to assess the role of CBS in monocytosis during atherosclerosis in the 
Apoe
-/-













mice had altered cholesterol level compared with Apoe
-/- 
mice, likely reflecting the 
role of ApoE in regulating cholesterol removal and that this process is somewhat affected by 
CBS deficiency (Fig. 2.1). This created a challenge for our studies. First, the degree of 
monocytosis is highly dependent on the lipid profile in each mouse model. Higher levels of 
cholesterol paralleled increased monocyte levels during extended WTD feeding, and improved 
lipid profile through transgenic ApoA I expression or reconstituted HDL injection reversed the 




mice showed a 





interpretation of the results since the change in monocyte counts could arise from the altered 
cholesterol level instead of any specific effect of CBS deficiency. Second, the extent of 
atherosclerotic lesions could also be significantly impacted by the cholesterol level in the 
circulation. Since we eventually need to assess the specific impact of CBS deficiency and any 
potential changes in monocyte level on the development of atherosclerosis, it is of critical 
importance that the CBS deficient animals share similar cholesterol levels with the animals that 
have intact CBS expression. To achieve that, we transplanted female Ldlr
-/-







 mice.  






 mice on chow diet. 





cholesterol level. This proves to be a difficult model for investigating the effect of monocyte 
level on atherosclerosis since cholesterol level also decreased along with monocytes.  
 
To assess if any potential effect of CBS deficiency is specific to the context of atherogenesis 
associated monocytosis, we also transplanted WT or Cbs
-/-
 bone marrow into Ldlr
-/-
 mice as 
controls. As mentioned above, Ldlr
-/-
 mice do not develop monocytosis during the first 10 weeks 
of WTD feeding (Murphy, Akhtari et al. 2011), presumably due to the fact that on a cellular 
level, cholesterol efflux mechanism are intact despite of the hypercholesterolemic environment 
in the circulation. If WT bone marrow and Cbs
-/-
 bone marrow transplanted Ldlr
-/-
 mice do not 
differ in their monocyte levels, it would imply that CBS does not have an impact on the baseline 
homeostasis of monocytes but rather mediates the cellular cholesterol-driven myeloid expansion.  
After bone marrow transplantation, we allowed the mice to recover for 5 weeks, during which a 
chow diet was administered. After that, all mice received WTD feeding for up to 9 weeks. 
Circulating monocyte, neutrophil and cholesterol levels were monitored after 5 and 8 weeks of 
WTD feeding. After 9 weeks of WTD feeding, we sacrificed the mice and analysed the 






Figure 2.2 Overview of study design. Ldlr
-/-
 mice were lethally irradiated and transplanted with 






, WT or Cbs
-/-
 mice. Five weeks after the bone marrow 
transplant, the recipient mice will be administered with WTD and monitored for circulating 
leukocyte and cholesterol levels after 5 and 8 weeks of WTD feeding. After 9 weeks of WTD 
feeding, the mice will be euthanized and analyzed for atherosclerosis development in the aorta 
and the HSPC level and proliferation activity in the bone marrow and the spleen. Given the 
potential differential effect of monocytosis on early and advanced lesions, atherosclerotic lesions 















































 mice were 
transplanted into 8-10 female Ldlr
-/-
 recipient mice that are lethally irradiated.(Murphy, Akhtari 
et al. 2011) To confirm the success of bone marrow reconstitution,  I collected mouse blood 
through tail vein bleeding, purify the DNA of peripheral blood using UltraClean BloodSpin 
DNA isolation kit (Mo Bio Laboratories), and assessed the quantity of CBS gene via Q-PCR five 
weeks after bone marrow transplantation. Once the success of bone marrow reconstitution was 
confirmed, recipient mice were fed a Western Type Diet (WTD, 21% milk fat, 0.2% cholesterol; 
catalog no. TD88137; Harlan Teklad) for up to 9 weeks. All mice were housed at Columbia 
University Medical Center according to animal welfare guidelines. Animals had ad libitum 
access to food and water. 
Total Cholesterol  
Mouse blood was collected through tail vein bleeding followed by centrifugation for 10 minutes 
at 10,000 x g using a refrigerated centrifuge to remove blood cells and platelets. Cholesterol 
levels were measure from the plasma using the Cholesterol E kit (Wako Diagnostics) as per the 
manufactures instructions.    





Mouse blood was drawn freshly via tail bleeding and white blood cell counts were determined 
with the FORCYTE Veterinary Analyzer (Oxford Science, Inc).  
Flow Cytometry - Blood Leukocytes  
To identify monocytes and neutrophils from whole blood, I collected mouse blood via tail 
bleeding into EDTA lined tubes which were immediately incubated on ice.  RBCs were lysed by 
incubating in ice cold BD pharm Lyse (BD Bioscience) for 10 min and WBCs were centrifuged, 
washed and resuspened in HBSS (0.1% BSA w/v, 5mM EDTA). Cells were stained with a 
cocktail of antibodies against CD45-APC-Cy7, Ly6-C/G-PerCP-Cy5.5 (BD Phamingen), 
CD115-APC and CD11b-FITC (eBioscience). Samples were analyzed on an LSR-II (BD 
















 (Gr-1).(Murphy, Woollard 
et al. 2008, Gower, Wu et al. 2011)  
Flow Cytometry – Bone marrow and spleen HSPCs 
Bone marrow was harvested by flushing the femurs and tibias with ice-cold PBS. Spleen was 
crushed on a cell strainer on a 50ml falcon tube to release the cells into ice-cold PBS. Bone 
marrow or spleen cells were then incubated with BD Pharm Lyse on ice for 10 min, followed by 
centrifugation to remove lysed RBCs. The remaining cells were then resuspened in HBSS (0.1% 
BSA w/v, 5mM EDTA) and incubated with a cocktail of antibodies to lineage committed cells 
(CD45R, CD19, CD11b, CD3e, TER-119, CD2, CD8, CD4, Ly-6G: All FITC, eBioscience), 
Sca1-Pacific Blue, ckit-APC Cy7. For the further identification of progenitor cells, anti-bodies to 
CD16/CD32 (FcγRII/III) and CD34 were used. HSPCs were identified as lin-Sca1+ ckit+,   CMPs 






















(Donato, Martinez-Romero et al. 2009, Han, Kitamoto et 
al. 2009, Gimm, Wiese et al. 2010) To assess the proliferation activity of HSPCs and progenitor 
cells, we permeablized the cells by incubating them with BD CytoFix/CytoPerm (554714) buffer 
followed by washing 3 times with ice-cold Perm/Wash buffer. The cells were then suspended in 
HBSS containing 3µM of DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride, Invitrogen). 
Stained cells were analyzed using BD LSRII running FACSDiVa software and results were 
analyzed and presented using FlowJo software. 
Statistics 
Statistical analysis was done using 2-tailed parametric Student’s t test when comparing two 







To assess the bone marrow transplantation efficiency, I isolated the genomic DNA of circulating 







 bone marrow transplanted mice had 90% less Cbs DNA in the circulating 
blood cells when compared with WT and Apoe
-/-
 bone marrow transplanted mice, respectively, 
indicating that the vast majority of the leukocytes in the circulation are derived from donor mice 
(Fig 2.3).   
 
Figure 2.3. Bone marrow reconstitution rate was assessed with Q-PCR analysis of circulating 
blood DNA. WT bone marrow transplanted mice was defined as 100% when comparing WT and 
Cbs
-/-
 bone marrow transplanted mice, and the average Cbs DNA level of Apoe
-/-
 bone marrow 






 bone marrow 
transplanted mice. Mice reconstituted with bone marrow from CBS deficient mice had more than 










































Cholesterol levels were also monitored in these mice and at two different time points, and all 
four groups of mice showed similar total cholesterol levels (Fig. 2.4).  
 
Figure 2.4.  Ldlr
-/- 








 bone marrow had 
similar levels of cholesterol throughout the study. Results are shown as Mean±SEM. N=8 for 
each group. 
 
CBS deficiency decreased circulating monocyte level specifically in the Apoe
-/- 
bone marrow 





 bone marrow transplanted mice had 25% fewer monocytes than Apoe
-/-
 bone 
marrow transplanted mice after 5 weeks of WTD feeding, and the reduction was even more 
pronounced (42%) after 8 weeks of WTD feeding (Fig. 2.5 A). In contrast, Cbs
-/-
 bone marrow 
transplanted mice did not differ in their monocyte level compared with the WT bone marrow 

















 subpopulations as the ratio between the two populations was unaltered. (Fig. 2.6).  
  
 
Figure 2.5. CBS deficiency reduced monocyte level specifically in Apoe
-/-
 bone marrow 
transplanted mice. (A) Ldlr
-/-




 bone marrow had significantly less 
monocyte in the circulation compared with the Apoe
-/-
 bone marrow transplanted mice. CBS 
deficiency did not alter the monocyte content in Apoe
+/+ 
bone marrow transplanted mice. (B) 





marrow transplanted mice. Results are shown as Mean±SEM. Statistical analysis was done using 




































monocytes up to 8 weeks after WTD feeding. Results are shown as Mean±SEM. Statistical 
analysis was done using 2-tailed parametric Student’s t test and there is no significant difference 
between WT and Cbs
-/-
  or between Apoe
-/-




 bone marrow transplanted mice. 
N=10 for WT and Cbs
-/-




 bone marrow 
transplanted mice. 
 
CBS deficiency decreased HSPC expansion in bone marrow and spleen specifically in the Apoe
-/- 
bone marrow transplanted mice.  
Previous studies have suggested that HSPC expansion might underlie the monocytosis observed 
in atherosclerosis models through enhanced CBS signaling (Yvan-Charvet, Pagler et al. 2010, 
Murphy, Akhtari et al. 2011). I compared the HSPC counts and proliferative activity in the bone 











 bone marrow transplanted mice had 






cells or LSKs), 28% fewer common myeloid progenitor 
cells (CMPs), 24% fewer granulocyte-monocyte progenitor cells (GMPs) and 36% 
megakaryocyte-erythroid progenitor cells (MEPs) in the bone marrow (Fig. 2.7 A).  And in the 
spleen, CBS deficiency decreased HSPCs, CMPs, GMPs and MEPs by 35%, 37%, 33% and 33%, 





 group was associated with a decrease in the proliferation, measured as the percentage of cells in 
the S/G2/M phase of the cell cycle (Figure 2.7 B); however, progenitor cell proliferative activity 
was unchanged, suggesting that decreased levels were secondary to decreased LSK proliferation. 





transplanted mice compared with the Apoe
-/-
 bone marrow transplanted mice (Figure 
2.8B). In contrast, CBS deficiency did not alter the number or proliferative activity of HSPCs on 
an Apoe
+/+ 
background in either the bone marrow or the spleen. The lack of CBS also had no 
effect on the progenitor cells except for deceased GMPs in the spleen.  
Apoe
-/-
 mice are known to develop splenomegaly upon WTD feeding (Murphy, Akhtari et al. 
2011), a feature that is believed to reflect the increased cellularity in the spleen. Consistent with 
the decreased number and proliferation activity of the splenic HSPCs, the spleen size is also 




 group compared with the Apoe
-/-
 bone marrow transplanted group 
(Figure 2.9). This reduction of spleen weight was not seen in the Apoe
+/+ 
bone marrow 





 Figure 2.7. CBS deficiency decreased HSPC expansion in bone marrow specifically in the Apoe
-
/- 
background. (A) Bone marrow and spleen cells are analyzed for its HSPC and progenitor cell 
counts using flowcytometry. Results are shown as a percentage of total cells. (B) HSPC and 
progenitor cells in the bone marrow are assessed for their proliferation activity using Dapi 
staining. Cells in the S, G2 or M phase are quantified and expressed as a percentage of each 
population. Results are shown as mean±SEM. Statistical analysis was done using 2-tailed 









 bone marrow transplanted mice.. *p<0.05 v.s. Apoe
-/-
, **p<0.01 v.s. Apoe
-/-
,  ## 
p<0.01 v.s. WT, ###p<0.001 v.s. WT. 
 
Figure 2.8. CBS deficiency resulted in a marked reduction of HSPC in the spleen specifically in 
the Apoe
-/- 
bone marrow transplanted mice. (A) Spleen cells are analyzed for HSPC and 
progenitor cell counts using flowcytometry. Results are shown as a percentage of total cells. (B) 
HSPC and progenitor cells in the spleen are assessed for their proliferation activity using Dapi 





population. Results are shown as Mean±SEM. Statistical analysis was done using 2-tailed 





 bone marrow transplanted mice.. *p<0.05 v.s. Apoe
-/-





, # p<0.05 v.s. WT, ###p<0.001 v.s. WT. 
 
Figure 2.9 CBS deficiency selectively reduced spleen weight in Apoe
-/-
 bone marrow 
transplanted Ldlr
-/-
 mice. After euthanasia, spleen of each mouse was extracted and weighed. 
Results are shown as Mean±SEM. Statistical analysis was done using 2-tailed parametric 
Student’s t test. N=10 for WT and Cbs-/- bone marrow transplanted mice, N=9 Apoe-/- Cbs-/- bone 









These data suggest that CBS deficiency reversed HSPC proliferation and expansion associated 
with ApoE deficiency in the bone marrow and the spleen, leading to reduced monocyte level in 
the circulation without a significant impact on cholesterol level. 
Lack of endogenous ApoE in HSPCs leads to cellular cholesterol retention due to defective 
cholesterol efflux through ABC transporters. This results in increased lipid raft formation and 
elevated cellular level of CBS, which in turn causes cell-autonomous myeloid expansion 






 bone marrow had significantly 
less HSPC expansion and monocyte production compared with Apoe
-/-
 bone marrow transplanted 
mice, suggesting that CBS mediates the cell-autonomous expansion of HSPCs. Importantly, CBS 
appears to mediate monocytosis specifically in the context of cellular cholesterol retention 
without interrupting the baseline hematopoiesis, since Ldlr
-/- 
mice receiving WT and Cbs
-/-
 bone 
marrow did not differ in their monocyte level or HSPC proliferation. Therefore, targeting CBS 
could be a safe strategy to reverse monocytosis during atherosclerosis since it only affects 
accelerated monocytosis due to hypercholesterolemia but does not have an impact on the 
baseline level of monocyte production and maintenance.  




 monocytes due 
to CBS deficiency (Fig. 2.6), indicating that the lack of CBS reduced both monocyte populations 
equally. Since Ly6C
hi 
monocytes are known for more readily entering the atherosclerotic lesions 
due to their higher level of CCR2 expression, it is important that they are being targeted by this 
intervention in order for it to have an impact on the progression of atherosclerosis. 
Although monocytosis during atherosclerosis is primarily a result of cellular level of cholesterol, 












mice (Yvan-Charvet, Pagler et al. 2010), and increased cholesterol level 






mice (Murphy, Akhtari 
et al. 2011). The fact that CBS deficiency reduced monocyte level in the absence of any 







 bone marrow transplanted mice should be 
attributed to the lack of CBS signaling instead of altered lipid profile.  







mice, there appears to be subtle differences in the driving force 
behind the reduction. In the bone marrow, a decrease in the proliferation activity of LSK cells 
resulted in reduced number of LSKs, and production of CMPs and GMPs in the bone marrow 
decreased due to reduced LSKs even though the proliferation activity of these progenitor cells 
did not differ significantly. In the spleen, however, both LSK and GMP showed reduced 
percentage of cells in the S/G2/M phase, therefore, the reduced number of GMPs was secondary 
to both reduced LSK and decreased GMP proliferation. This is consistent with previous studies 
that identified the spleen as a primary site for extramedullary myelopoiesis during atherosclerosis 
through enhanced GMP proliferation (Robbins, Chudnovskiy et al. 2012). The same study 
identified the enhanced production of GM-CSF and IL-3 by splenic cells to be responsible for 
the GMP expansion in the spleen. The next chapter will focus on identifying the source of GM-
CSF and IL-3 in the spleen and the mechanism behind this elevated production of these 
cytokines in the setting of atherosclerosis.  
One limitation of the study is the gating strategy adopted at the time of the experiment. As 











 bone marrow transplanted mice had significantly less Lin
-
 cells. 
Therefore, the fact that less LSK cells were observed in the Apoe
-/-
 bone marrow transplanted 
mice may simply reflect a lack of Lin
-
 cells. The interpretation of study might be complicated as 
a result. A better approach might have been to gate for the number of Lin
-
 cells, and compare 
LSK cells as a percentage of Lin
-
 cells. The data presented here were LSK cells as a percentage 
of total viable singular cells; therefore, our interpretation is that LSK cells as a percentage of all 






Chapter 3: IRA B cells contribute to myeloid expansion through elevated GM-CSF 
production in the spleen during atherogenesis. 
Introduction 
In parallel to our laboratory’s discovery of cell-autonomous proliferation of the HSPCs in bone 
marrow of Apoe
-/- mice, Fillip Swirski’s group described another mechanism wherein GM-CSF 
and IL-3 mediated GMP proliferation in the spleen give rise to enhanced monocyte production 
(Robbins, Chudnovskiy et al. 2012). These two mechanisms are not mutually exclusive and quite 
possibly work in synergy to enhance myeloid expansion, and CBS could play a central role in 
mediating the proliferative response in both scenarios.  
Indeed, bone marrow derived HSPCs are known to traffic through blood to extramedullary sites 
including the spleen where they proliferate and give rise to myeloid cells in both the steady-state 
and during inflammation (Wright, Wagers et al. 2001, Massberg, Schaerli et al. 2007, Dutta, 
Courties et al. 2012). Recent studies have highlighted the significance of the spleen as a site of 
extramedullary myeloproliferation during pathological processes (Swirski, Nahrendorf et al. 
2009, Dutta, Courties et al. 2012).  This phenomenon has also been reported in animal models of 





 mice showed infiltration of HSPCs in the lung, spleen and liver 
mediated through an IL-23/IL-17/G-CSF signaling axis (Westerterp, Gourion-Arsiquaud et al. 
2012).  
In Swirski group’s study, WTD fed Apoe-/- mice developed splenomegaly upon WTD feeding 
due to enhanced HSPC proliferation and myelopoiesis in the spleen (Robbins, Chudnovskiy et al. 





showed positive staining for GM-CSF and IL-3, although the identity of these cells was not 
specified in this study.  
In a subsequent study, Swirski and colleagues described a new class of B cells that produce GM-
CSF and IL-3 upon LPS stimulation in WT mice (Rauch, Chudnovskiy et al. 2012). Although 
GM-CSF has previously been thought to be produced by endothelial cells, T cells and 
macrophages, flow cytometry analysis found a marked increase in GM-CSF positive cells in the 





















 and constitute a unique class of B 
cells distinct from previously described B cell subsets. Again, these cells are found to increase in 
abundance specifically in the spleen but not the bone marrow after LPS treatment. Adoptive 
transfer of various GFP+ cell types demonstrated that peritoneal cavity B1a cells gave rise to 
these splenic GM-CSF producing B cells. The authors termed these splenic cells Innate Response 
Activator (IRA) B cells given the established role of GM-CSF in innate immunity. During 
inflammatory responses, B1a cells become activated and migrate to the spleen in a TLR-
4/MYD88-dependent fashion. These B1a cells then differentiate into IRA B cells in the spleen 
where they play an important role in protecting the host against sepsis. Mice deficient in IRA B 
cells demonstrated defective bacterial clearance and greater mortality after cecal ligation and 
puncture (CLP)-induced sepsis (Rauch, Chudnovskiy et al. 2012). 
Interestingly, B1a cells express CBS on the cell surface, and blockade of CBS through a 
neutralizing antibody prevented B1a cells from developing into IRA B cells in vitro, suggesting a 






Figure 3.1. Development and function of IRA B cells. The B1a cells in the peritoneal cavity 
encounter endotoxin stimuli and respond with TLR-4/MYD88 activation. These signals induce 
B1a cells to mobilize to the spleen where they develop into IRA B cells that produce GM-CSF 
and IL-3. Both B1a and IRA B cells express CBS and amplify the GM-CSF signals through a 
positive feedback loop. GM-CSF activates innate immunity and protects the host against sepsis 
and may also play a role in HSPC and GMP expansion that leads to monocytosis.  
Given the similarities between IRA B cells and the splenic cells that produce GM-CSF and IL-3 
in the WTD-fed Apoe
-/- 
mice, I hypothesized that it is IRA B cells that produce GM-CSF and IL-
3 in the spleen in high fat diet-fed Apoe
-/- 
mice, and that the CBS plays a critical role in 























/J) mice were purchased from Jackson Laboratories (Bar 
Harbor, ME). WT and Apoe
-/- 
were fed on WTD for up to 5 weeks before the analysis.  
Flow Cytometry – Bone marrow and spleen IRA B cells 
Bone marrow and spleen leukocytes were collected as described in the previous chapter. These 
cells were incubated with the following antibodies for 30 minutes on ice: IgM-APC, CD23-PE 
Cy7 and CD19-APC Cy7, followed by centrifugation to remove the antibodies. The cells were 
washed once in ice-cold HBSS once and permeabilization in BD CytoFix/CytoPerm (554714) 
buffer and Perm/Wash buffer as described before. The cells were then   incubated in Perm/Wash 
buffer containing GM-CSF-PE antibody for 30 minutes on ice, followed by resuspension in 
HBSS containing 3µM of DAPI. Stained cells were analyzed using BD LSRII running 








. In the 
settings where cells surface CBS was detected, CBS-PE antibody was included in the incubation 
before permeabilization of the cells, and a GM-CSF-FITC antibody is used after the 
permeabilization. Results were analyzed and presented using FlowJo software. 
Flow Cytometry – Peritoneal B1a cells 
Peritoneal leukocytes were collected by through lavage of the peritoneal cavity with ice-cold 
PBS. After centrifugation, the cells were resuspended in BD PharmLyse buffer to remove any 
red blood cells. The cells were then stained in HBSS buffer with the following antibodies: B220-















Statistical analysis was done using 2-tailed parametric Student’s t test when comparing two 







Extramedullary myeloid expansion is associated with increased IRA B cells in the spleen   
To test if IRA B cells are involved in the elevated GM-CSF and IL-3 production in the spleen in 
the setting of atherosclerosis, I first compared the number of IRA B cells in the spleen of WT 
and Apoe
-/- 
mice after WTD feeding.  Compared with WT mice, Apoe
-/-
 mice showed a dramatic 
increase in number of IRA B cells (Fig. 3.2 B) as well as the % of cells in the G2M phase of the 
cell cycle in the spleen (Fig. 3.2 C). Consistent with earlier reports (Rauch, Chudnovskiy et al. 






Figure 3.2 Increased IRA B cells in the spleen in the setting of atherosclerosis. (A, B) WT and 
Apoe
-/-
 mice were subject to WTD feeding for 5 weeks and spleen cells were analyzed for their 
IRA B cell content using flowcytometry. (C) The proliferation activity of IRA B cells was 
assessed using Dapi staining and quantification of cells in the S, G2 and M phases. Results are 

























































Figure 3.3 No difference was observed in IRA B cell counts or proliferation activity in the bone 
marrow during atherogenesis. (A) WT and Apoe
-/-
 mice were fed a WTD for 5 weeks, (B)and 
bone marrow cells were analyzed for their IRA B cell content using flowcytometry. (C) The 
proliferation activity of spleen IRA B cells was assessed using Dapi staining and quantification 




































































































CBS mediates IRA B cell expansion in the setting of atherosclerosis.   
Previous study demonstrated that B1a cells failed to give rise to IRA B cells in response to LPS 
treatment in the presence of a neutralizing antibody against CBS (Rauch, Chudnovskiy et al. 
2012), suggesting that CBS is involved in the development of IRA B cells. Our laboratory 
reported that Apoe
-/-
 mice had increased cell surface level of CBS in HSPCs due to defective 
cholesterol efflux and enhanced lipid raft formation (Murphy, Akhtari et al. 2011). These 
observations led us to hypothesize that the enhanced IRA B cell formation in the spleen could be 
due to elevated CBS expression in B1a and/or IRA B cells. Importantly, I show for the first time 
that Apoe
-/-
 mice have increased CBS level on the IRA B cells (Fig. 3.4). The elevated level of 
CBS could possibly explain the enhanced proliferation of IRA B cells in the spleen given that 
GM-CSF and IL-3 generally promotes cell proliferation and survival.  
 
Figure 3.4. Increased CBS expression on the IRA B cells in Apoe
-/-
 mice. After 5 weeks of WTD 
feeding, splenic IRA B cells from WT and Apoe
-/-
 mice were isolated followed by analysis of cell 
surface level of CBS with flowcytometry.   Results are shown as mean±SEM. N=4 for WT and 
N=5 for Apoe
-/-










Although the number of B1a cells in the peritoneal cavity did not differ between the WT and 
Apoe
-/- 
mice (Fig. 3.5A), B1a cells did demonstrate increased cell surface level of CBS as well 
(Fig. 3.5 B). These findings suggest that IRA B cell expansion could at least partially be 
explained by the enhanced development of IRA B cells from B1A cells and increased IRA B cell 
proliferation as a result of the increased CBS expression on these two cell types.   
 
Figure 3.5. Increased CBS expression on peritoneal B1a cells in Apoe
-/-
 mice. After 5 weeks of 
WTD feeding, peritoneal cells from WT and Apoe
-/-
 mice were isolated followed by analysis of 
(A) total B1a cell content and (B) cell surface level of CBS with flowcytometry.  Results are 








To confirm the role of CBS in IRA B cell development during myeloid expansion, I compared 
the number of IRA B cells in Ldlr
-/- 






 bone marrows. 
Indeed, CBS deficiency decreased the number of IRA B cells in the spleen as well as their 
proliferative activity (Fig. 3.6), suggesting an essential role for CBS in elevating the number of 
IRA B cells during atherosclerosis.  
 
Figure 3.6. CBS deficiency decreased the IRA B cell proliferation. Ldlr
-/- 







 bone marrow followed by WTD feeding for 9 weeks. (A) IRA B 
cells in the spleen were quantified using flowcytometry. (B) The number of proliferating IRA B 
cells was determined using Dapi staining and flowcytometry and expressed as percentage of IRA 




























































Our data suggest that defective cholesterol efflux due to cellular ApoE deficiency leads to 
increased CBS level in B1a cells, rendering these cells more efficiently transformed into IRA B 
cells in the spleen where they produce GM-CSF and IL-3. These cytokines then enhance myeloid 
expansion by promoting GMP proliferation and monocyte development; they can also act in an 
autocrine fashion to support further IRA B cells development and proliferation.  
The fact that IRA B cell expansion and enhanced GM-CSF and IL-3 production occur in the 
spleen but not the bone marrow underscore the importance of the spleen as an extramedullary 
site for monocyte production. The cell-autonomous HSPC expansion in the bone marrow likely 
constitutes one of the initial responses to cellular cholesterol retention during 
hypercholesterolemia especially when cellular cholesterol efflux pathways are defective. LSK 
cells subsequently migrate to the spleen where they encounter the GM-CSF and IL-3 produced 
by IRA B cells. In the spleen, the elevated CBS level in HSPCs also enhances their ability to 
proliferate, and the elevated number of IRA B cells further exacerbates the myeloid expansion. 
Therefore, the HSPC expansion in the bone marrow and increased GM-CSF and IL-3 production 
in the spleen act in synergy to promote monocytosis. A recent study reported that impaired 
cholesterol efflux leads to enhanced HSPC mobilization from the bone marrow to the spleen, and 
this is associated with increased circulating G-CSF, a cytokine known to mobilize stem cells 
from the bone marrow (Westerterp, Gourion-Arsiquaud et al. 2012). This represents a further 
mechanism that amplifies the myeloid expansion during atherosclerosis.  
The upregulation of CBS in IRA B cells resembles what was observed in the bone marrow and 
spleen HSPCs with defective cholesterol efflux, indicating that cholesterol retention and 





These data suggest that altered CBS expression due to cholesterol accumulation occur in various 
cell types and leads to several different pathological responses. For example, unpublished data 
(Ganda A and Tall AR) from our group suggests that patients with chronic kidney disease (CDK), 
a condition that has been associated with increased risk of cardiovascular diseases, have elevated 
blood monocyte counts, decreased ABCA1 expression and increased cholesterol level and CBS 
level in the circulating monocytes. Our work in the mouse model suggests that in human CKD 
this may be the result of increased CBS expression in the HSPCs in the bone marrow and spleen. 
These HSPCs likely proliferate and differentiate into myeloid cells more robustly due to the 
increased CBS level due to defective cholesterol efflux and might serve as a link between CKD 
and increased risk of cardiovascular diseases.  
It should also be noted that TLR-4 activation was identified as a critical step during LPS induced 
IRA cell development. Mice deficient in TLR-4 or MYD88 failed to develop IRA B cells and 
monocytosis in response to LPS injection (Rauch, Chudnovskiy et al. 2012). Animal models with 




 macrophages showed more robust inflammatory gene expression upon TLR-4 ligand 
treatment compared with WT macrophages, and the increase was abolished in macrophages 
lacking either TLR-4 or MYD88 (Yvan-Charvet, Welch et al. 2008). Similarly, TLR-4 or 
MYD88 deficiency in Apoe
-/- 
mice ameliorated atherosclerosis through decreased 
proinflammatory cytokines IL-12 and MCP-1 (Michelsen, Wong et al. 2004). Given the 
mechanism uncovered here, enhanced TLR-4 signaling could also potentially contribute to 
increased IRA B cell production in Apoe
-/- 
mice, and previously reported atheroprotective effect 
of TLR-4 or MYD88 deficiency might be partially due to its effect on IRA B cells production 





Chapter 4. CBS deficiency produces a complex atherosclerosis phenotype. 
Introduction 
Research in the past two decades has firmly established a central role for monocyte-derived 
macrophages in atherogenesis.  Therefore, it is plausible that a reduction in monocyte level 
would result in decreased monocyte entry and hence decreased atherosclerotic lesion size and 
macrophage foam cell content. As summarized in the Introduction, clinical studies have 
identified monocyte levels to be an independent risk factor for atherosclerotic cardiovascular 
diseases, and numerous studies in animal models suggest monocytosis underlies the development 
of atherosclerosis.  Ldlr
-/- 
mice receiving CD45.1 WT bone marrow and CD45.2 Apoe
-/- 
bone 
marrow had markedly more CD45.2 monocyte in the circulation, and this was associated with a 
preferential accumulation of CD45.2 Apoe
-/- 
macrophage foam cells in lesions (Murphy, Akhtari 
et al. 2011). Since CD45.1 and CD45.2 monocytes shared the same environment, this indicates 
that the cell intrinsic expansion of monocytes likely caused an increase in their accumulation in 
plaques – cell extrinsic factors such as an increase in MCP-1 expression by Apoe-/- macrophages 
in lesions should have affected both populations of monocytes equally.  Since CBS deficiency 
only decreased monocyte level in Apoe
-/- 
bone marrow transplanted Ldlr
-/- 
mice but not the 
Apoe
+/+
 bone marrow transplanted mice, I expected to see a decrease in atherosclerotic lesions 
only in the Apoe
-/- 
groups.  
It should be noted that atherosclerosis is a complex inflammatory disorder that involves a variety 
of cells in the immunological system. Therefore, after histological analysis of the aorta via 
hematoxylin and eosin (H&E) staining, I aimed to also assess the impact of CBS deficiency on 
other cells types, especially those that are known to be influenced by CBS ligands, such as DCs, 





by determining the cellular contents using a combination of approaches including 






H&E and macrophage staining of atherosclerotic lesions 
Following euthanasia, the heart of each mouse was perfused with ice-cold PBS and fixed in 
formaline. The aorta roots were then sectioned at 8-μm intervals, and 6 sections of the same 
order from each mouse were then stained with H&E to assess overall tissue morphology.  
For the quantification of macrophage content within the lesions, a section of the same order from 
each mouse was counterstained with Harris Hematoxylin and an antibody against F4/80. Images 
were digitized and quantified using Olympus IX 70 fluorescence microscope. 
Flow cytometry – Tregs and DCs in the spleen and lymphnodes 
Tregs and DCs were isolated from the iliac lymph nodes and the spleen following a procedure 
described before. Briefly, lymph nodes or spleen were diced and digested in 30% Collagenase 
(Sigma C2674) in PBS at 37 C. The digested tissue was then passed through a syringe for several 
times and filtered through a 40μm cell strainer. The cells were collected through centrifugation 
followed by removal of red blood cells with BD Pharm Lyse. White blood cells were then 
collected, washed and resuspended in HBSS containing the appropriate antibodies. The 
antibodies used for Treg surface staining are: CD4-FITC and CD25-AP, after permeabilization 







. In a separate preparation, white blood cells from the spleen and lymph 
nodes were stained with the following antibodies: CD45-APC Cy7, MHC-II-PE, CD11c-A700. 











 DCs. The samples were examined on a BD LSR II flow cytometer and data were 
analyzed with FlowJo software. 





After euthanizing each mouse, the heart and the arterial tree were perfused with 10mL of ice-
cold PBS. The aortic root was placed in OCT medium and was flash-frozen on dry ice. Using a 
cryomicrotome, sections were cut serially at 8-μm intervals, generating 25 sections that spanned 
the entire aortic root, and mounted on slides. For comparison of lesional mRNA expression 
between the groups, the sections of the same order were used for each mouse.  Atherosclerotic 
lesions were visualized and selectively captured using a PALM laser capture microdissection 
(LCM) machine. RNA was isolated using the RNeasy Micro Kit (Qiagen). Linear amplification 
of the RNA was performed using the MessageAmp II aRNA Kit (Ambion). The purity of the 
obtained RNA was determined using a NanoDrop machine (Thermo Scientific). RNA with an 
A260/280 of >1.8 was used for cDNA synthesis. cDNA conversion of the amplified RNA was 
performed using the SuperScript VILO cDNA Synthesis Kit (Invitrogen). qPCR was performed 







Reduction of monocytes due to CBS deficiency did not decrease atherosclerotic lesion size 







mice compared with Apoe
-/- 
bone marrow transplanted ones, there was no 
difference in atherosclerotic lesion between the groups (Fig. 4.1). Two-way ANOVA analysis 
revealed a statistically significant effect of ApoE deficiency on the lesion size as expected from 
earlier studies (Fazio, Babaev et al. 1997), but no significant effect of CBS deficiency.  
 
Figure 4.1. CBS deficiency did not reduce atherosclerotic lesion size. Aortic root was isolated 
and fixed with formalin. Paraffin sessions were prepared and subject to H&E staining. N=24-26 
for each group. Two-way ANOVA revealed a significant change in lesion size due to ApoE 
deficiency (p<0.0001) but not CBS deficiency (p=0.12). 
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To further assess the composition of the aortic lesions, I stained the lesions for macrophage 
content using an antibody against F4/80, a macrophage marker. This revealed a decreased 




bone marrow transplanted mice 
compared to Apoe
-/- 
bone marrow transplanted mice (Fig. 4.2). Quantification of the non-cellular 





transplanted mice (Fig. 4.2) although this difference did not reach statistical significance. This 
shift in atherosclerotic lesion composition indicates that the reduction in monocyte level might 
have contributed to decreased monocyte entry into the lesions. However, the athero-protective 
effect of decreased monocytes could potentially be counteracted by a detrimental processes 
associated with CBS deficiency that could facilitate necrotic core formation. These two opposing 
effects appeared to counterbalance each other leading to no significant change in lesion area. 
               




























































































Figure 4.2. CBS deficiency resulted in altered lesional composition in Apoe
-/-
 bone marrow 
transplanted Ldlr
-/-   
mice. (A) macrophage content of the lesions were identified using F/40 
staining on the same set of paraffin sections of aortic root preparation used for H&E staining. N 
=16 for Apoe
-/-




 (B) Necrotic core area was identified and quantified under 
a microscope as the non- cellular regions of the lesions. Results are shown as mean±SEM and t-
test was performed to compare the two groups. N=9 for Apoe
-/-






Decreased Tregs and ABCG1 expression due to CBS deficiency counteract the atheroprotive 
effect of reduced monocyte level 
When searching for a mechanism that might counteract the athero-protective effect of reduced 
monocyte level, I first assessed the possibility that the lack of IL-5 signaling in B1a cells might 
contribute to decreased athero-protective IgM secretion in CBS deficient mice. However,  as 
determined in the laboratory of Dr Joseph Witztum, CBS deficiency did not decrease but rather 
increased the circulating level of EO6, an IgM secreted by B1a cells that has been shown to exert 
atheroprotetive roles in Ldlr
-/- 
mice (Fig. 4.3). This finding was unlikely to explain our lesion 











-/-   
mice. Dilution curves of serum IgM binding to the monoclonal anti-
T15/EO6 antibody were produced by pooling 8 mice from each group. (Data provided by Joseph 
Witztum) 
 
Next, I examined the potential involvement of DCs which rely on GM-CSF for their 
development and, upon activation, engage Tregs to exert anti-inflammatory roles and attenuate 
atherosclerosis development via secretion of anti-inflammatory cytokines such as IL-10 (Mallat, 
Gojova et al. 2003, Ait-Oufella, Salomon et al. 2006, Mor, Planer et al. 2007, Ganesh, Cheatem 
et al. 2009, Takeda, Yamashita et al. 2010, Bhattacharya, Gopisetty et al. 2011, Subramanian, 
Thorp et al. 2013). Although the numbers of these cells were unaltered in the lymph nodes (Fig. 




bone marrow transplanted mice compared with Apoe
-/- 





presumably due to the decreased GM-CSF production as a result of reduced IRA B cells as I 
described in the previous chapter.  
 







 DCs in the lymph nodes were quantified and further 
categorized as (A) CD11b
+
 and (B) CD11b
-





) remained and (D) Tregs, expressed as a percentage of total CD4
+
 T cells, were 







Figure 4.5. CBS deficiency decreased the number of DCs and Tregs in the spleen. DCs in the 






. Both (A) CD11b
+
 and (B) CD11b
-
 DCs were 















) , expressed as a 
percentage of total CD4
+
 T cells, were also reduced in the CBS deficient mice. Results are shown 
as mean±SEM, and t-test was performed to compare the two groups. N=5. 
 
As determined by laser capture microdissection (LCM) analysis and qPCR, there were also 
trends of decreases in Foxp3 and IL-10 mRNA level in lesions (Fig 4.6 A and B). These 
differences did not reach statistical significance probably due to the large variances that are 





result of CBS deficiency might contributed to the lack of decrease of atherosclerotic lesions 
despite the reduced monocyte level.  
Manikandan et al. previously reported that in DC-specific MYD88 deficient mice the reduced 
Tregs is linked to an increase of MCP-1 due to decreased TGFβ. However, despite the reduced 
Tregs, CBS deficient mice demonstrated decreased MCP-1 and increased TGFβ mRNA levels 
(Fig. 4.6 C and D). The apparent discrepancy is possibly due to the complexity of different cell 
types involved in the two different animal models. In our model, this reduced MCP-1 is likely 
secondary to the reduced monocyte entry since macrophages are a major source of MCP-1, and 
reduced MCP-1 could also contribute to further reducing macrophage accumulation given its 







Figure 4.6.  Tregs and IL-10 mRNA were reduced in CBS deficient mice. Lesional mRNA was 
extracted using LCM. RT-PCR and qPCR were utilized to measure the transcription of (A) 
FoxP3 and (B) IL-10. Results are shown as mean±SEM, and t-test was performed to compare the 
two groups. N=10. 
 
Finally, since GM-CSF has been reported to enhance the expression of ABC transporters that are 
critical for maintaining cellular cholesterol homeostasis (Thomassen, Barna et al. 2007), I tested 





bone marrow transplanted Ldlr
-/- 
mice. Indeed, Q-PCR analysis of the LCM samples 
revealed that while Abcg1 mRNA readily detected in the Apoe
-/- 
bone marrow transplanted Ldlr
-/- 




bone marrow transplanted animals (Fig. 4.7 
A). Abca1 mRNA level, however, was not altered by CBS deficiency (Fig. 4.7 B). Previous 
studies have shown that ABCG1 deficiency leads to a marked increase in susceptibility of 
macrophages to apoptosis in response to oxidized LDL loading, reflecting the accumulation of 
toxic oxysterols (Tarling, Bojanic et al. 2010, Yvan-Charvet, Pagler et al. 2010).  This serves as 









Figure 4.7. CBS deficiency diminished the expression of ABCG1. (A) ABCG1 and (B) 
ABCA1mRNA in the atherosclerotic lesions were measured as mentioned above. Results are 







Our results showed that CBS deficiency led to a decrease in macrophage content and MCP-1 
levels in the lesion of Apoe
-/-- 
bone marrow transplanted Ldlr
-/- 
mice. However, these effects were 
counteracted by the lack of athero-protective Tregs in the spleen and likely in atherosclerotic 
lesions and defective macrophage cholesterol efflux due to the lack of Abcg1 expression in 
lesional macrophages. These factors on balance produced no significant changes in the 
atherosclerotic lesion area but shifted the lesion composition by decreasing macrophage foam 
cell content and increasing the necrotic core area.  
GM-CSF has been shown to regulate DCs in atherosclerotic lesions (Shaposhnik, Wang et al. 
2007, Zhu, Chen et al. 2009), and recent literature has highlighted the atheroprotective role of 
DC-activated Tregs during atherogenesis (Choi, Cheong et al. 2011, Subramanian, Thorp et al. 
2013). Specifically, DC-activated regulatory T cells (Tregs) suppress IFN-γ, TNF-α and MCP-1 
production in the lesions, contributing to reduced inflammation and recruitment of monocytes to 




bone marrow transplanted mice likely explained the decrease in DCs and Tregs in the spleen. 
Although difficult to quantify accurately as T cells are rare in lesions and LCM samples 
relatively large lesions areas, the lesions in these mice probably also had less Tregs suggesting 
that the loss of atheroproective  Tregs due to CBS deficiency could partially explain the lack of 




 group despite of the significant 
reduction of monocytes. 
ABCG1 is known to play an important role in macrophage survival, and impaired cholesterol 
efflux due to loss of Abcg1leads to apoptosis of these cells. Deficiency of ABCG1 alone or a 





stress induced apoptosis (Yvan-Charvet, Pagler et al. 2010), and ABCG1 deficiency caused 
decreased cellularity and increased macrophage apoptosis in Apoe
-/-
 mice (Tarling, Bojanic et al. 
2010).   
GM-CSF is an established regulator of ABC transporter expression. Lack of GM-CSF reduced 
ABCG1 expression in the alveolar macrophages and decreased ABCA1 expression in the 
atherosclerotic lesions of Apoe
-/-
 mice (Ditiatkovski, Toh et al. 2006). Therefore, the lack of 




bone marrow transplanted Ldlr
-/- 
mice might contribute to 
macrophage death and necrotic core formation.  
Nonetheless, it is somewhat surprising to find a lack of atheroprotective impact of CBS 




bone marrow transplanted mice had 26% less circulating 
monocytes after 8 weeks of WTD feeding. Further review of the literature suggest that blockade 
of circulating monocyte does not always result in attenuated atherosclerosis. In Apoe
-/-
 mice 
transplanted with bone marrow from CD11b-diphtheria toxin (DT) receptor transgenic mice, 
administration of DT markedly reduced peripheral blood monocyte level and decreased the 
extent of plaque formation during the early stage of atherosclerosis. However, chronic DT 
treatment of these mice did not alter plaque extent or macrophage content (Stoneman, Braganza 
et al. 2007). Similarly, although CCR2
-/-
 bone marrow transplanted Apoe
-/-
 mice had reduced 
plaques in early atherosclerosis, repopulation of Apoe
-/-
 mice with established plaques showed no 
effect on the lesion development (Guo, de Waard et al. 2005). Recent studies suggest that local 
proliferation of macrophages might sustain inflammatory response and wound repair without 
recruitment of monocytes into the inflammatory site, and this has led to the speculation that the 
development of advanced atherosclerotic lesions might rely more on macrophage proliferation 





reduced monocyte level might delay the initiation of atherosclerosis; however, the long-term 







Chapter 5: Discussion 
Our study has provided direct evidence that CBS plays a key role in mediating monocytosis in 
the standard Apoe
-/-
 mouse model of atherosclerosis. In the bone marrow, CBS is required for the 
hypercholesterolemia-driven HSPC and myeloid expansion; in the spleen, CBS increases GM-
CSF and IL-3 production by facilitating IRA B cell development and in turn enhances 
extramedullary myeloid proliferation and monocytosis. Despite these potentially atheroprotective 
effects, CBS deficiency also decreased the number of atheroprotective Tregs and decreased the 
expression of ABCG1, causing increased macrophage apoptosis and necrotic core formation. 




 mice underscores the 
roles of CBS in multiple cell types and the complexity of the pathogenesis of atherosclerosis.  
Teleology of the cholesterol-driven expansion of myeloid cells  
Mammalian cells have evolved to develop intricate mechanisms to coordinate cellular growth 
with nutrient availability (Yuan, Xiong et al. 2013). Both extracellular nutrient and intracellular 
metabolites have been identified as key regulatory factors of cell proliferation with abundance of 
nutrients leading to accelerated growth whereas lack of nutrient causing the cells to adjust 
growth rate to cope with stress.  
For example, mTORC1has been identified as a sensor of amino acids, the building blocks of 
proteins. In a well-nourished cell, intracellular amino acids signal to activate mTORC1 that leads 
to protein synthesis and cell growth. Under severe nutrient constraint, inactivation of 
mTORC1not only shuts down protein synthesis but also lifts the inhibition on autophagy where 






Another well-established mechanism involves AMP-activated protein kinase (AMPK), a master 
regulator of metabolism to maintain energy homeostasis during biological processes. ATP 
hydrolysis to ADP or AMP provides energy for most biological processes in a eukaryotic cell, 
and AMPK monitors cellular energy levels by sensing ATP:ADP ratio. AMPK stays inactive 
when the environment offers adequate carbon source (e.g. glucose) and oxygen for catabolism 
and keeps a high ratio of ATP:ADP; when there is a lack of energy supply, increased AMP/ATP 
ratio leads to the activation of AMPK, which restores energy homeostasis by promoting 
catabolism and inhibiting ATP-consuing processes.  Because cell growth and proliferation are 
energy-intensive processes, it is not surprising that AMPK activation also arrest cell proliferation 
at the G1-S boundary through p53 phosphorylation (Hardie 2007). 
Cholesterol is an essential building block of the cellular membrane. Therefore, it makes 
teleological sense for a cell to couple its growth rate with the availability of cellular cholesterol.  
This study together with previous publications from our lab provide insight into how IRA B cells, 
monocytes and HSPCs detect cholesterol level and translate availability of cholesterol into 
elevated CBS level that promotes cell growth.  
Although such nutrient-sensing mechanism is evolutionarily favorable as it ensures the cells only 
proliferate in the presence of sufficient nutrient, it became maladaptive under the pathological 
condition of hypercholesterolemia. Chronically elevated cellular levels of cholesterol in the 
HSPCs lead to hypersensitivity to GM-CSF and IL-3, and once the HSPCs expand and mobilize 
to the spleen, they encounter the GM-CSF and IL-3 produced by the IRA B cells, which also 
proliferate as a result of increased cholesterol level, further driving the myeloid expansion. CBS 
is central to multiple steps during this pathological state and is a major mediator of monocytosis 





Many nutrient sensing mechanisms that are coupled with cell growth have been exploited for 
their potential to arrest cancerous cell growth. mTOR signaling pathways has been pursued as a 
target for cancer therapy (Meric-Bernstam and Gonzalez-Angulo 2009), and AMPK is 
considered a metabolic tumor suppressor and a promising therapeutic target for cancer treatment 
(Luo, Zang et al. 2010). Given the increasing evidence for the cholesterol driven myeloid cell 
expansion, our studies could provide clues for treating leukemia by interfering the cholesterol 
sensing machinery.  
 
Early lesions versus advanced lesions during atherosclerosis 
Our data suggest that while monocyte levels might be associated with atherosclerosis, their 
contribution to plaque formation is highly dependent on the stage of atherosclerosis development. 
This notion has been championed by the pioneering studies of Ira Tabas’ group in the past 
decade. Macrophage apoptosis differentially affect early and advanced stage atherosclerosis. 
Macrophage death during early lesions is associated with smaller lesions and less plaque 
progress due to the effective clearance of the apoptotic cells by neighboring macrophages 
through efferocytosis and the anti-inflammatory mediators derived from the efferocytes. 
However, in advanced lesions where efferocytosis is impaired, macrophage death cause 
secondary necrotic cell death, and the decreased lesional cellularity does not contribute to 
decreased plaque burden but instead leads to necrotic core formation and increase plaque 
vulnerability (Tabas 2010).  
Similarly, monocytosis might also impact atherosclerosis lesion development in a phase-specific 
manner. Monocytosis could result in earlier onset of atherosclerosis since elevated number of 





leukocytes take residency in the lesions, increased monocyte number may no longer significantly 
contribute to increased plaque burden, and local cell proliferation may sustain the size of the 
plaques.  These observations further enforce the concept that early lesions and advanced lesions 
involve different pathological processes that should be carefully differentiated.  
Clinical Implications 
Our data suggest that targeting CBS signaling is an effective way to reverse monocytosis during 
atherosclerosis. Importantly, this approach is unlikely to dirupt baseline myelopoiesis since CBS 
only reversed the monocytosis in the Apoe
-/- 
bone marrow transplanted mice but not the Apoe
+/+ 
bone marrow transplanted mice. Although CBS deficiency in our model showed a complex 
atherosclerosis phenotype in advanced lesions where necrotic core was dominant, targeted 
inhibition of CBS or its ligands can still possibly ameliorate plaque development in early lesions, 
especially given the strong association between monocytosis and atherosclerosis in clinical 
settings. 
MOR103, a monoclonal human IgG1 neutralizing antibody against GM-CSF, has been 
developed and is being tested in clinical trials for the treatment of rheumatoid arthritis (RA) 
(ClinicalTrials.gov identifier: NCT01023256 and NCT01517282) (Deiss, Brecht et al. 2013). RA 
is a chronic inflammatory disease characterized by synovial tissue infiltration with macrophages, 
dendritic cells (DCs), lymphocytes and neutrophils. Local production of GM-CSF was found in 
synovial fluid and is believed to mediate the progression of RA by promoting differentiation, 
growth and effector functions of neutrophils and macrophages (Cornish, Campbell et al. 2009). 
During the Phase I/II multicenter, randomized, placebo-controlled study,  multiple doses of 
MOR103 led to a robust reduction of the desease after as early as 4 weeks while demonstrating 





α antibody was also found to be successful in managing RA in a Phase II trial (ClinicalTrials.gov 
identifier: NCT00771420 and NCT01706926).  Administration of MOR103 and Mavrilimumab 
could potentially be a therapeutic strategy for the management for early stage atherosclerosis.  
Future directions 
Further analysis of the atherosclerotic lesions  
Although our data showed that reduced monocyte level does not significantly ameliorate 





is indeed due to enhanced macrophage death, Tunnel Staining of the 
lesions should be carried out to identify apoptotic macrophages.  
Given the increasing evidence of the involvement of ER stress during macrophage apoptosis in 
advanced lesions, it would be of interest to compare cholesterol loading induced ER stress 






 macrophages. In vitro studies showed that 7-
ketocholesterol  is sufficient to trigger this apoptosis pathway that involves the activation of 
inositol 1,4,5-triphosphate (IP3) receptor (IP3R) via CHOP-induced ERO1-α (ER oxidase 1 α) 
(Li, Mongillo et al. 2009). It is also known that ABCG1 protects macrophages from oxidized 
low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol (Terasaka, 




 bone marrow transplanted mice had significantly less 





have increased 7-ketocholesterol that might result in enhanced apoptosis through ER stress.  
Investigate the role of monocytosis in early atherosclerosis 
Considering the significant reduction of monocyte level in CBS deficient mice, it is plausible to 
speculate that the atherosclerotic lesions at an earlier stage might be reduced in these animals. I 













their lesion progression after 4 week of western type die. Pilot study has shown that these lesions 
are free of necrotic core, indicating that these are early stage lesions where efferocytosis 
machinery is intact. These experiments would provide evidence for the potential involvement of 
monocytosis during the onset of atherogenesis. 
Possible molecular mechanism of increased CBS level in cells with defective cholesterol efflux 
Our data suggested that increased CBS level in various cell types contributes to monocytosis 
through multiple mechanisms, it is of interest to understand the underlying molecular mechanism.  
A recent study in our laboratory delineated the molecular mechanisms behind cholesterol-driven 
cell surface expression of another hematopoietic growth factor receptor. Transplantation of 
ABCG4 deficient bone marrow into Ldlr
-/- 
mice resulted in thrombocytosis and accelerated 
atherosclerosis, reflecting increased cell surface expression of the thrombopoietin (TPO) receptor 
c-MPL and enhanced proliferation of megakaryocyte progenitors (MkPs). ABCG4 appears to 
mediate cholesterol efflux in these MkPs, and ABCG4 deficiency caused cholesterol retention in 
the membrane and inhibition of the cholesterol sensing LYN kinase.  Prolonged activation of c-
MPL by TPO usually results in activation of LYN, which in turn phosphorylates Casitas b-
lineage lymphoma (c-Cbl), an E-3 ubiquitin ligase that targets thrombopoietin receptor (MPL) 
for ubiquitination and subsequent degradation. Cholesterol retentions cause by ABCG4 
deficiency appeared to inhibit LYN kinase activity and therefore disrupts this the negative 
feedback loop, leading to increased cell surface level of c-MPL (Andrew, Nora et al. 2013).  






 mice. CBS is known to undergo degradation upon agonistic ligation (Martinez-
Moczygemba and Huston 2001). Activation of CBS by GM-CSF has been reported to induce c-





to induce Lyn activity in an in vitro kinase activity assay (Torigoe, O'Connor et al. 1992). IL-5 
stimulation is also known to target CBS for ubiquitination and endosome trafficking, and 
ubiquitination deficient IL-5Rs accumulated on the cells surface in vitro (Lei, Mazumdar et al. 
2011). These evidences suggest that a similar negative feedback loop may regulate CBS-
mediated signaling. Prolonged activation of CBS likely leads to phosphorylation of c-Cbl by a 
Srk Family Kinase (SFK), and activated c-Cbl will target CBS for ubiquitination and 
proteasome-mediated degradation.  
Indeed, a loss-of-function c-Cbl mutation was recently reported to cause hypersensitivity to GM-
CSF (Niemeyer, Kang et al. 2010, Bunda, Kang et al. 2013). And loss of Lyn and Hck, two 
SFKs implied in c-Cbl phosphorylation, led to enhanced myeloproliferation mediated by GM-
CSF and IL-3 (Xiao, Hong et al. 2008). This evidence suggests that impaired c-Cbl 
phosphorylation by SFKs and disrupted downregulation of CBS could potentially be the 
mechanism behind the increased level of CBS observed in Apoe
-/-









Figure 5.1. Proposed molecular mechanism of increased CBS level in cells with defective 
cholesterol efflux. Prolonged activation of CBS by its ligands results in activation of SFKs that 
in turn phosphorylates c-Cbl, an E-3 ubiquitin ligase that targets CBS for ubiquitination and 
subsequent degradation. Cholesterol retentions cause by ApoE or ABCA1/ABCG1 deficiency 
could act to inhibit SFK kinase activity and therefore disrupts this negative feedback loop, 











Ait-Oufella, H., O. Herbin, J.-D. Bouaziz, C. Binder, C. Uyttenhove, L. Laurans, S. Taleb, E. 
Van Vré, B. Esposito, J. Vilar, J. Sirvent, J. Van Snick, A. Tedgui, T. Tedder and Z. Mallat 
(2010). "B cell depletion reduces the development of atherosclerosis in mice." The Journal of 
experimental medicine 207(8): 1579-1587. 
Ait-Oufella, H., B. L. Salomon, S. Potteaux, A. K. Robertson, P. Gourdy, J. Zoll, R. Merval, B. 
Esposito, J. L. Cohen, S. Fisson, R. A. Flavell, G. K. Hansson, D. Klatzmann, A. Tedgui and Z. 
Mallat (2006). "Natural regulatory T cells control the development of atherosclerosis in mice." 
Nat Med 12(2): 178-180. 
Ait-Oufella, H., S. Taleb, Z. Mallat and A. Tedgui (2011). "Recent advances on the role of 
cytokines in atherosclerosis." Arteriosclerosis, thrombosis, and vascular biology 31(5): 969-979. 
Andrew, J. M., B. Nora, Y.-C. Laurent, B. W. Carrie, B. Neha, R. Adili, W. Yiming, A. S. James, 
L. L. Ross, N. Heyu, R. T. Alan and W. Nan (2013). "Cholesterol efflux in megakaryocyte 
progenitors suppresses platelet production and thrombocytosis." Nature Medicine 19. 
Averill, L. E., R. C. Meagher and R. G. Gerrity (1989). "Enhanced monocyte progenitor cell 
proliferation in bone marrow of hyperlipemic swine." Am J Pathol 135(2): 369-377. 
Bagley, C., J. Woodcock, T. Hercus, M. Shannon and A. Lopez (1995). "Interaction of GM-CSF 
and IL-3 with the common beta-chain of their receptors." Journal of Leukocyte Biology 57(5): 
739-746. 
Bagley, C. J., J. M. Woodcock, F. C. Stomski and A. F. Lopez (1997). "The structural and 
functional basis of cytokine receptor activation: lessons from the common beta subunit of the 
granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors." 
Blood 89(5): 1471-1482. 
Barter, P., A. Gotto, J. LaRosa, J. Maroni, M. Szarek, S. Grundy, J. Kastelein, V. Bittner, J.-C. 
Fruchart and I. Treating to New Targets (2007). "HDL cholesterol, very low levels of LDL 
cholesterol, and cardiovascular events." The New England journal of medicine 357(13): 1301-
1310. 
Bhattacharya, P., A. Gopisetty, B. B. Ganesh, J. R. Sheng and B. S. Prabhakar (2011). "GM-
CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive 
Tregs by different mechanisms." Journal of Leukocyte Biology 89(2): 235-249. 
Binder, C., K. Hartvigsen, M.-K. Chang, M. Miller, D. Broide, W. Palinski, L. Curtiss, M. Corr 
and J. Witztum (2004). "IL-5 links adaptive and natural immunity specific for epitopes of 
oxidized LDL and protects from atherosclerosis." The Journal of clinical investigation 114(3): 
427-437. 
Bodzioch, M., E. Orsó, J. Klucken, T. Langmann, A. Böttcher, W. Diederich, W. Drobnik, S. 
Barlage, C. Büchler, M. Porsch-Ozcürümez, W. Kaminski, H. Hahmann, K. Oette, G. Rothe, C. 
Aslanidis, K. Lackner and G. Schmitz (1999). "The gene encoding ATP-binding cassette 





Bogunovic, M., F. Ginhoux, J. Helft, L. Shang, D. Hashimoto, M. Greter, K. Liu, C. Jakubzick, 
M. A. Ingersoll and M. Leboeuf (2009). "Origin of the lamina propria dendritic cell network." 
Immunity 31(3): 513-525. 
Boring, L., J. Gosling, M. Cleary and I. Charo (1998). "Decreased lesion formation in CCR2-/- 
mice reveals a role for chemokines in the initiation of atherosclerosis." Nature 394(6696): 894-
897. 
Braunersreuther, V., S. Steffens, C. Arnaud, G. Pelli, F. Burger, A. Proudfoot and F. Mach 
(2008). "A novel RANTES antagonist prevents progression of established atherosclerotic lesions 
in mice." Arteriosclerosis, thrombosis, and vascular biology 28(6): 1090-1096. 
Braunersreuther, V., A. Zernecke, C. Arnaud, E. Liehn, S. Steffens, E. Shagdarsuren, K. 
Bidzhekov, F. Burger, G. Pelli, B. Luckow, F. Mach and C. Weber (2007). "Ccr5 but not Ccr1 
deficiency reduces development of diet-induced atherosclerosis in mice." Arteriosclerosis, 
thrombosis, and vascular biology 27(2): 373-379. 
Brizzi, M., L. Formato, P. Dentelli, A. Rosso, M. Pavan, G. Garbarino, M. Pegoraro, G. Camussi 
and L. Pegoraro (2001). "Interleukin-3 stimulates migration and proliferation of vascular smooth 
muscle cells: a potential role in atherogenesis." Circulation 103(4): 549-554. 
Brown, M. and J. Goldstein (1997). "The SREBP pathway: regulation of cholesterol metabolism 
by proteolysis of a membrane-bound transcription factor." Cell 89(3): 331-340. 
Brown, M., Y. Ho and J. Goldstein (1980). "The cholesteryl ester cycle in macrophage foam 
cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters." The Journal 
of biological chemistry 255(19): 9344-9352. 
Bunda, S., M. Kang, S. Sybingco, J. Weng, H. Favre, D. Shin, M. Irwin, M. Loh and M. Ohh 
(2013). "Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile 
Myelomonocytic Leukemia." Cancer research 73(8): 2540-2550. 
Caligiuri, G., A. Nicoletti, B. Poirier and G. Hansson (2002). "Protective immunity against 
atherosclerosis carried by B cells of hypercholesterolemic mice." The Journal of clinical 
investigation 109(6): 745-753. 
Caux, C., B. Vanbervliet, C. Massacrier, C. Dezutter-Dambuyant, B. de Saint-Vis, C. Jacquet, K. 
Yoneda, S. Imamura, D. Schmitt and J. Banchereau (1996). "CD34+ hematopoietic progenitors 
from human cord blood differentiate along two independent dendritic cell pathways in response 
to GM-CSF+TNF alpha." The Journal of experimental medicine 184(2): 695-706. 
Caux, C., B. Vanbervliet, C. Massacrier, I. Durand and J. Banchereau (1996). "Interleukin-3 
cooperates with tumor necrosis factor alpha for the development of human dendritic/Langerhans 
cells from cord blood CD34+ hematopoietic progenitor cells." Blood 87(6): 2376-2385. 
Chapman, C. M. L., J. P. Beilby, B. M. McQuillan, P. L. Thompson and J. Hung (2004). 
"Monocyte Count, But Not C-Reactive Protein or Interleukin-6, Is an Independent Risk Marker 
for Subclinical Carotid Atherosclerosis." Stroke 35(7): 1619-1624. 
Chawla, A., J. Repa, R. Evans and D. Mangelsdorf (2001). "Nuclear receptors and lipid 





Choi, J.-H., C. Cheong, D. Dandamudi, C. Park, A. Rodriguez, S. Mehandru, K. Velinzon, I.-H. 
Jung, J.-Y. Yoo, G. Oh and R. Steinman (2011). "Flt3 signaling-dependent dendritic cells protect 
against atherosclerosis." Immunity 35(5): 819-831. 
Choi, J. H., C. Cheong, D. B. Dandamudi, C. G. Park, A. Rodriguez, S. Mehandru, K. Velinzon, 
I. H. Jung, J. Y. Yoo, G. T. Oh and R. M. Steinman (2011). "Flt3 signaling-dependent dendritic 
cells protect against atherosclerosis." Immunity 35(5): 819-831. 
Coller, B. S. (2005). "Leukocytosis and Ischemic Vascular Disease Morbidity and Mortality." 
Arteriosclerosis, Thrombosis, and Vascular Biology 25(4): 658-670. 
Combadière, C., S. Potteaux, J.-L. Gao, B. Esposito, S. Casanova, E. Lee, P. Debré, A. Tedgui, P. 
Murphy and Z. Mallat (2003). "Decreased atherosclerotic lesion formation in 
CX3CR1/apolipoprotein E double knockout mice." Circulation 107(7): 1009-1016. 
Combadière, C., S. Potteaux, M. Rodero, T. Simon, A. Pezard, B. Esposito, R. Merval, A. 
Proudfoot, A. Tedgui and Z. Mallat (2008). "Combined inhibition of CCL2, CX3CR1, and 
CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in 
hypercholesterolemic mice." Circulation 117(13): 1649-1657. 
Cornish, A., I. Campbell, B. McKenzie, S. Chatfield and I. Wicks (2009). "G-CSF and GM-CSF 
as therapeutic targets in rheumatoid arthritis." Nature reviews. Rheumatology 5(10): 554-559. 
Deiss, A., I. Brecht, A. Haarmann and M. Buttmann (2013). "Treating multiple sclerosis with 
monoclonal antibodies: a 2013 update." Expert Rev Neurother 13(3): 313-335. 
Ditiatkovski, M., B.-H. Toh and A. Bobik (2006). "GM-CSF deficiency reduces macrophage 
PPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice." 
Arteriosclerosis, thrombosis, and vascular biology 26(10): 2337-2344. 
Donahue, R., J. Seehra, M. Metzger, D. Lefebvre, B. Rock, S. Carbone, D. Nathan, M. Garnick, 
P. Sehgal and D. Laston (1988). "Human IL-3 and GM-CSF act synergistically in stimulating 
hematopoiesis in primates." Science (New York, N.Y.) 241(4874): 1820-1823. 
Donato, M. T., A. Martinez-Romero, N. Jimenez, A. Negro, G. Herrera, J. V. Castell, J. E. 
O'Connor and M. J. Gomez-Lechon (2009). "Cytometric analysis for drug-induced steatosis in 
HepG2 cells." Chem Biol Interact 181(3): 417-423. 
Doran, A., M. Lipinski, S. Oldham, J. Garmey, K. Campbell, M. Skaflen, A. Cutchins, D. Lee, D. 
Glover, K. Kelly, E. Galkina, K. Ley, J. Witztum, S. Tsimikas, T. Bender and C. McNamara 
(2012). "B-cell aortic homing and atheroprotection depend on Id3." Circulation research 110(1): 
12. 
Döring, Y., M. Drechsler, S. Wantha, K. Kemmerich, D. Lievens, S. Vijayan, R. Gallo, C. 
Weber and O. Soehnlein (2012). "Lack of neutrophil-derived CRAMP reduces atherosclerosis in 
mice." Circulation research 110(8): 1052-1056. 
Dranoff, G., A. Crawford, M. Sadelain, B. Ream, A. Rashid, R. Bronson, G. Dickersin, C. 
Bachurski, E. Mark and J. Whitsett (1994). "Involvement of granulocyte-macrophage colony-
stimulating factor in pulmonary homeostasis." Science (New York, N.Y.) 264(5159): 713-716. 
Drechsler, M., R. Megens, M. van Zandvoort, C. Weber and O. Soehnlein (2010). 






Drechsler, M., R. T. A. Megens, M. van Zandvoort, C. Weber and O. Soehnlein (2010). 
"Hyperlipidemia-Triggered Neutrophilia Promotes Early Atherosclerosis / Clinical Perspective." 
Circulation 122(18): 1837-1845. 
Dutta, P., G. Courties, Y. Wei, F. Leuschner, R. Gorbatov, C. Robbins, Y. Iwamoto, B. 
Thompson, A. Carlson, T. Heidt, M. Majmudar, F. Lasitschka, M. Etzrodt, P. Waterman, M. 
Waring, A. Chicoine, A. van der Laan, H. Niessen, J. Piek, B. Rubin, J. Butany, J. Stone, H. 
Katus, S. Murphy, D. Morrow, M. Sabatine, C. Vinegoni, M. Moskowitz, M. Pittet, P. Libby, C. 
Lin, F. Swirski, R. Weissleder and M. Nahrendorf (2012). "Myocardial infarction accelerates 
atherosclerosis." Nature 487(7407): 325-329. 
Dutta, P., G. Courties, Y. Wei, F. Leuschner, R. Gorbatov, C. S. Robbins, Y. Iwamoto, B. 
Thompson, A. L. Carlson, T. Heidt, M. D. Majmudar, F. Lasitschka, M. Etzrodt, P. Waterman, 
M. T. Waring, A. T. Chicoine, A. M. van der Laan, H. W. Niessen, J. J. Piek, B. B. Rubin, J. 
Butany, J. R. Stone, H. A. Katus, S. A. Murphy, D. A. Morrow, M. S. Sabatine, C. Vinegoni, M. 
A. Moskowitz, M. J. Pittet, P. Libby, C. P. Lin, F. K. Swirski, R. Weissleder and M. Nahrendorf 
(2012). "Myocardial infarction accelerates atherosclerosis." Nature 487(7407): 325-329. 
Emanuel, P. D. (2008). "Juvenile myelomonocytic leukemia and chronic myelomonocytic 
leukemia." Leukemia 22(7): 1335-1342. 
Fazio, S., V. Babaev, A. Murray, A. Hasty, K. Carter, L. Gleaves, J. Atkinson and M. Linton 
(1997). "Increased atherosclerosis in mice reconstituted with apolipoprotein E null 
macrophages." Proceedings of the National Academy of Sciences of the United States of 
America 94(9): 4647-4652. 
Feldman, D. L., T. C. Mogelesky, B. F. Liptak and R. G. Gerrity (1991). "Leukocytosis in 
rabbits with diet-induced atherosclerosis." Arterioscler Thromb 11(4): 985-994. 
Foster, P., S. Hogan, A. Ramsay, K. Matthaei and I. Young (1996). "Interleukin 5 deficiency 
abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model." The 
Journal of experimental medicine 183(1): 195-201. 
Friedman, G., A. Klatsky and A. Siegelaub (1974). "The leukocyte count as a predictor of 
myocardial infarction." The New England journal of medicine 290(23): 1275-1278. 
Ganda, A., M. Magnusson, L. Yvan-Charvet, B. Hedblad, G. Engström, D. Ai, T. Wang, R. 
Gerszten, O. Melander and A. Tall (2013). "Mild renal dysfunction and metabolites tied to low 
HDL cholesterol are associated with monocytosis and atherosclerosis." Circulation 127(9): 988-
996. 
Ganesh, B. B., D. M. Cheatem, J. R. Sheng, C. Vasu and B. S. Prabhakar (2009). "GM-CSF-
induced CD11c+CD8a—dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion 
resulting in suppression of autoimmune thyroiditis." International Immunology 21(3): 269-282. 
Gautier, E., T. Huby, J. Witztum, B. Ouzilleau, E. Miller, F. Saint-Charles, P. Aucouturier, M. 
Chapman and P. Lesnik (2009). "Macrophage apoptosis exerts divergent effects on atherogenesis 
as a function of lesion stage." Circulation 119(13): 1795-1804. 
Gebuhrer, V., J. Murphy, J. Bordet, M. Reck and J. McGregor (1995). "Oxidized low-density 
lipoprotein induces the expression of P-selectin (GMP140/PADGEM/CD62) on human 





Gillum, R., M. Mussolino and J. Madans (1997). "Coronary heart disease incidence and survival 
in African-American women and men. The NHANES I Epidemiologic Follow-up Study." 
Annals of internal medicine 127(2): 111-118. 
Gimm, T., M. Wiese, B. Teschemacher, A. Deggerich, J. Schodel, K. X. Knaup, T. Hackenbeck, 
C. Hellerbrand, K. Amann, M. S. Wiesener, S. Honing, K. U. Eckardt and C. Warnecke (2010). 
"Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of 
hypoxia-inducible factor-1." FASEB J 24(11): 4443-4458. 
Glass, C. K. and J. L. Witztum (2001). "Atherosclerosis. the road ahead." Cell 104(4): 503-516. 
Gordon, T., W. Castelli, M. Hjortland, W. Kannel and T. Dawber (1977). "High density 
lipoprotein as a protective factor against coronary heart disease. The Framingham Study." The 
American journal of medicine 62(5): 707-714. 
Gower, R. M., H. Wu, G. A. Foster, S. Devaraj, I. Jialal, C. M. Ballantyne, A. A. Knowlton and 
S. I. Simon (2011). "CD11c/CD18 expression is upregulated on blood monocytes during 
hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1." Arterioscler 
Thromb Vasc Biol 31(1): 160-166. 
Greter, M., J. Helft, A. Chow, D. Hashimoto, A. Mortha, J. Agudo-Cantero, M. Bogunovic, E. 
Gautier, J. Miller, M. Leboeuf, G. Lu, C. Aloman, B. Brown, J. Pollard, H. Xiong, G. Randolph, 
J. Chipuk, P. Frenette and M. Merad (2012). "GM-CSF controls nonlymphoid tissue dendritic 
cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells." 
Immunity 36(6): 1031-1046. 
Gu, L., Y. Okada, S. Clinton, C. Gerard, G. Sukhova, P. Libby and B. Rollins (1998). "Absence 
of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein 
receptor-deficient mice." Molecular cell 2(2): 275-281. 
Guo, J., V. de Waard, M. Van Eck, R. Hildebrand, E. van Wanrooij, J. Kuiper, N. Maeda, G. 
Benson, P. Groot and T. Van Berkel (2005). "Repopulation of apolipoprotein E knockout mice 
with CCR2-deficient bone marrow progenitor cells does not inhibit ongoing atherosclerotic 
lesion development." Arteriosclerosis, thrombosis, and vascular biology 25(5): 1014-1019. 
Hamilton, J. (2002). "GM-CSF in inflammation and autoimmunity." Trends in immunology 
23(8): 403-408. 
Han, X., S. Kitamoto, Q. Lian and W. A. Boisvert (2009). "Interleukin-10 facilitates both 
cholesterol uptake and efflux in macrophages." J Biol Chem 284(47): 32950-32958. 
Hardie, D. (2007). "AMP-activated/SNF1 protein kinases: conserved guardians of cellular 
energy." Nature reviews. Molecular cell biology 8(10): 774-785. 
Hashimoto, D., J. Miller and M. Merad (2011). "Dendritic cell and macrophage heterogeneity 
in vivo." Immunity 35(3): 323-335. 
Hercus, T. R., D. Thomas, M. A. Guthridge, P. G. Ekert, J. King-Scott, M. W. Parker and A. F. 
Lopez (2009). "The granulocyte-macrophage colony-stimulating factor receptor: linking its 
structure to cell signaling and its role in disease." Blood 114(7): 1289-1298. 
Hermansson, A., D. Ketelhuth, D. Strodthoff, M. Wurm, E. Hansson, A. Nicoletti, G. Paulsson-
Berne and G. Hansson (2010). "Inhibition of T cell response to native low-density lipoprotein 





Horikawa, K. and K. Takatsu (2006). "Interleukin-5 regulates genes involved in B-cell terminal 
maturation." Immunology 118(4): 497-508. 
Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu and R. Steinman 
(1992). "Generation of large numbers of dendritic cells from mouse bone marrow cultures 
supplemented with granulocyte/macrophage colony-stimulating factor." The Journal of 
experimental medicine 176(6): 1693-1702. 
Ishibashi, S., M. Brown, J. Goldstein, R. Gerard, R. Hammer and J. Herz (1993). 
"Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by 
adenovirus-mediated gene delivery." The Journal of clinical investigation 92(2): 883-893. 
Itoh, N., S. Yonehara, J. Schreurs, D. M. Gorman, K. Maruyama, A. Ishii, I. Yahara, K. Arai and 
A. Miyajima (1990). "Cloning of an interleukin-3 receptor gene: a member of a distinct receptor 
gene family." Science 247(4940): 324-327. 
Jenkins, S., D. Ruckerl, P. Cook, L. Jones, F. Finkelman, N. van Rooijen, A. MacDonald and J. 
Allen (2011). "Local macrophage proliferation, rather than recruitment from the blood, is a 
signature of TH2 inflammation." Science (New York, N.Y.) 332(6035): 1284-1288. 
Jia, T., N. Serbina, K. Brandl, M. Zhong, I. Leiner, I. Charo and E. Pamer (2008). "Additive 
roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during 
Listeria monocytogenes infection." Journal of immunology (Baltimore, Md. : 1950) 180(10): 
6846-6853. 
Kay, A., S. Ying, V. Varney, M. Gaga, S. Durham, R. Moqbel, A. Wardlaw and Q. Hamid 
(1991). "Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, 
and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous 
reactions in atopic subjects." The Journal of experimental medicine 173(3): 775-778. 
King, I., M. Kroenke and B. Segal (2010). "GM-CSF-dependent, CD103+ dermal dendritic cells 
play a critical role in Th effector cell differentiation after subcutaneous immunization." The 
Journal of experimental medicine 207(5): 953-961. 
Koltsova, E. and K. Ley (2011). "How dendritic cells shape atherosclerosis." Trends in 
immunology 32(11): 540-547. 
Kopf, M., F. Brombacher, P. Hodgkin, A. Ramsay, E. Milbourne, W. Dai, K. Ovington, C. Behm, 
G. Köhler, I. Young and K. Matthaei (1996). "IL-5-deficient mice have a developmental defect 
in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell 
responses." Immunity 4(1): 15-24. 
Koseki, M., K.-I. Hirano, D. Masuda, C. Ikegami, M. Tanaka, A. Ota, J. Sandoval, Y. 
Nakagawa-Toyama, S. Sato, T. Kobayashi, Y. Shimada, Y. Ohno-Iwashita, F. Matsuura, I. 
Shimomura and S. Yamashita (2007). "Increased lipid rafts and accelerated lipopolysaccharide-
induced tumor necrosis factor-alpha secretion in Abca1-deficient macrophages." Journal of lipid 
research 48(2): 299-306. 
Kouro, T., Y. Kikuchi, H. Kanazawa, K. Hirokawa, N. Harada, M. Shiiba, H. Wakao, S. Takaki 
and K. Takatsu (1996). "Critical proline residues of the cytoplasmic domain of the IL-5 receptor 
alpha chain and its function in IL-5-mediated activation of JAK kinase and STAT5." 





Kunjathoor, V., M. Febbraio, E. Podrez, K. Moore, L. Andersson, S. Koehn, J. Rhee, R. 
Silverstein, H. Hoff and M. Freeman (2002). "Scavenger receptors class A-I/II and CD36 are the 
principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid 
loading in macrophages." The Journal of biological chemistry 277(51): 49982-49988. 
Kyaw, T., C. Tay, H. Hosseini, P. Kanellakis, T. Gadowski, F. MacKay, P. Tipping, A. Bobik 
and B.-H. Toh (2012). "Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE 
mice attenuates atherosclerosis by potently ameliorating arterial inflammation." PloS one 7(1). 
Kyaw, T., C. Tay, A. Khan, V. Dumouchel, A. Cao, K. To, M. Kehry, R. Dunn, A. Agrotis and P. 
Tipping (2010). "Conventional B2 B cell depletion ameliorates whereas its adoptive transfer 
aggravates atherosclerosis." The Journal of Immunology 185(7): 4410-4419. 
Kyaw, T., C. Tay, S. Krishnamurthi, P. Kanellakis, A. Agrotis, P. Tipping, A. Bobik and B.-H. 
Toh (2011). "B1a B lymphocytes are atheroprotective by secreting natural IgM that increases 
IgM deposits and reduces necrotic cores in atherosclerotic lesions." Circulation research 109(8): 
830-840. 
Lahoute, C., O. Herbin, Z. Mallat and A. Tedgui (2011). "Adaptive immunity in atherosclerosis: 
mechanisms and future therapeutic targets." Nature reviews. Cardiology 8(6): 348-358. 
Lang, R., D. Metcalf, R. Cuthbertson, I. Lyons, E. Stanley, A. Kelso, G. Kannourakis, D. 
Williamson, G. Klintworth and T. Gonda (1987). "Transgenic mice expressing a hemopoietic 
growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal 
syndrome of tissue damage." Cell 51(4): 675-686. 
Lantz, C., J. Boesiger, C. Song, N. Mach, T. Kobayashi, R. Mulligan, Y. Nawa, G. Dranoff and 
S. Galli (1998). "Role for interleukin-3 in mast-cell and basophil development and in immunity 
to parasites." Nature 392(6671): 90-93. 
Lee, C. D., A. R. Folsom, F. J. Nieto, L. E. Chambless, E. Shahar and D. A. Wolfe (2001). 
"White blood cell count and incidence of coronary heart disease and ischemic stroke and 
mortality from cardiovascular disease in African-American and White men and women: 
atherosclerosis risk in communities study." Am J Epidemiol 154(8): 758-764. 
Lei, J., T. Mazumdar and M. Martinez-Moczygemba (2011). "Three lysine residues in the 
common β chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent 
receptor ubiquitination, endocytosis, and signaling." The Journal of biological chemistry 286(46): 
40091-40103. 
Lesnik, P., C. Haskell and I. Charo (2003). "Decreased atherosclerosis in CX3CR1-/- mice 
reveals a role for fractalkine in atherogenesis." The Journal of clinical investigation 111(3): 333-
340. 
Lewis, M., T. Malik, M. Ehrenstein, J. Boyle, M. Botto and D. Haskard (2009). 
"Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein 
receptor-deficient mice." Circulation 120(5): 417-426. 
Li, G., M. Mongillo, K.-T. Chin, H. Harding, D. Ron, A. Marks and I. Tabas (2009). "Role of 
ERO1-alpha-mediated stimulation of inositol 1,4,5-triphosphate receptor activity in endoplasmic 





Luo, Z., M. Zang and W. Guo (2010). "AMPK as a metabolic tumor suppressor: control of 
metabolism and cell growth." Future oncology (London, England) 6(3): 457-470. 
Lusis, A. J. (2000). "Atherosclerosis." Nature 407(6801): 233-241. 
Major, A., S. Fazio and M. Linton (2002). "B-lymphocyte deficiency increases atherosclerosis in 
LDL receptor-null mice." Arteriosclerosis, thrombosis, and vascular biology 22(11): 1892-1898. 
Mallat, Z., A. Gojova, V. Brun, B. Esposito, N. Fournier, F. Cottrez, A. Tedgui and H. Groux 
(2003). "Induction of a regulatory T cell type 1 response reduces the development of 
atherosclerosis in apolipoprotein E-knockout mice." Circulation 108(10): 1232-1237. 
Martinez-Moczygemba, M. and D. Huston (2001). "Proteasomal regulation of betac signaling 
reveals a novel mechanism for cytokine receptor heterotypic desensitization." The Journal of 
clinical investigation 108(12): 1797-1806. 
Martinez-Moczygemba, M. and D. Huston (2003). "Biology of common beta receptor-signaling 
cytokines: IL-3, IL-5, and GM-CSF." The Journal of allergy and clinical immunology 112(4): 
653. 
Massberg, S., P. Schaerli, I. Knezevic-Maramica, M. Kollnberger, N. Tubo, E. A. Moseman, I. V. 
Huff, T. Junt, A. J. Wagers, I. B. Mazo and U. H. von Andrian (2007). "Immunosurveillance by 
hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues." Cell 
131(5): 994-1008. 
Maxfield, F. and I. Tabas (2005). "Role of cholesterol and lipid organization in disease." Nature 
438(7068): 612-621. 
Meric-Bernstam, F. and A. Gonzalez-Angulo (2009). "Targeting the mTOR signaling network 
for cancer therapy." Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 27(13): 2278-2287. 
Mestas, J. and K. Ley (2008). "Monocyte-endothelial cell interactions in the development of 
atherosclerosis." Trends in cardiovascular medicine 18(6): 228-232. 
Metcalf, D. (1993). "Hematopoietic regulators: redundancy or subtlety?" Blood 82(12): 3515-
3523. 
Metcalf, D., C. Begley, G. Johnson, N. Nicola, A. Lopez and D. Williamson (1986). "Effects of 
purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult 
mice." Blood 68(1): 46-57. 
Metcalf, D., C. Begley, D. Williamson, E. Nice, J. De Lamarter, J. Mermod, D. Thatcher and A. 
Schmidt (1987). "Hemopoietic responses in mice injected with purified recombinant murine 
GM-CSF." Experimental hematology 15(1): 1-9. 
Michelsen, K., M. Wong, P. Shah, W. Zhang, J. Yano, T. Doherty, S. Akira, T. Rajavashisth and 
M. Arditi (2004). "Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces 
atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E." Proceedings 
of the National Academy of Sciences of the United States of America 101(29): 10679-10684. 
Michelsen, K. S., M. H. Wong, P. K. Shah, W. Zhang, J. Yano, T. M. Doherty, S. Akira, T. B. 





88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E." 
Proc Natl Acad Sci U S A 101(29): 10679-10684. 
Moon, B.-g., S. Takaki, K. Miyake and K. Takatsu (2004). "The role of IL-5 for mature B-1 cells 
in homeostatic proliferation, cell survival, and Ig production." Journal of immunology 
(Baltimore, Md. : 1950) 172(10): 6020-6029. 
Mor, A., D. Planer, G. Luboshits, A. Afek, S. Metzger, T. Chajek-Shaul, G. Keren and J. George 
(2007). "Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental 
atherosclerosis." Arterioscler Thromb Vasc Biol 27(4): 893-900. 
Mullick, A., P. Tobias and L. Curtiss (2005). "Modulation of atherosclerosis in mice by Toll-like 
receptor 2." The Journal of clinical investigation 115(11): 3149-3156. 
Murphy, A., M. Akhtari, S. Tolani, T. Pagler, N. Bijl, C.-L. Kuo, M. Wang, M. Sanson, S. 
Abramowicz, C. Welch, A. Bochem, J. Kuivenhoven, L. Yvan-Charvet and A. Tall (2011). 
"ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation 
in atherosclerotic lesions in mice." The Journal of clinical investigation 121(10): 4138-4149. 
Murphy, A. J., M. Akhtari, S. Tolani, T. Pagler, N. Bijl, C. L. Kuo, M. Wang, M. Sanson, S. 
Abramowicz, C. Welch, A. E. Bochem, J. A. Kuivenhoven, L. Yvan-Charvet and A. R. Tall 
(2011). "ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte 
accumulation in atherosclerotic lesions in mice." J Clin Invest 121(10): 4138-4149. 
Murphy, A. J., K. J. Woollard, A. Hoang, N. Mukhamedova, R. A. Stirzaker, S. P. McCormick, 
A. T. Remaley, D. Sviridov and J. Chin-Dusting (2008). "High-density lipoprotein reduces the 
human monocyte inflammatory response." Arterioscler Thromb Vasc Biol 28(11): 2071-2077. 
Murphy, J. and I. Young (2006). "IL-3, IL-5, and GM-CSF signaling: crystal structure of the 
human beta-common receptor." Vitamins and hormones 74: 1-30. 
Niemeyer, C., M. Kang, D. Shin, I. Furlan, M. Erlacher, N. Bunin, S. Bunda, J. Finklestein, K. 
Sakamoto, T. Gorr, P. Mehta, I. Schmid, G. Kropshofer, S. Corbacioglu, P. Lang, C. Klein, P.-G. 
Schlegel, A. Heinzmann, M. Schneider, J. Starý, M. van den Heuvel-Eibrink, H. Hasle, F. 
Locatelli, D. Sakai, S. Archambeault, L. Chen, R. Russell, S. Sybingco, M. Ohh, B. Braun, C. 
Flotho and M. Loh (2010). "Germline CBL mutations cause developmental abnormalities and 
predispose to juvenile myelomonocytic leukemia." Nature genetics 42(9): 794-800. 
Nishinakamura, R., A. Miyajima, P. Mee, V. Tybulewicz and R. Murray (1996). "Hematopoiesis 
in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-
3/interleukin-5 functions." Blood 88(7): 2458-2464. 
Nishinakamura, R., N. Nakayama, Y. Hirabayashi, T. Inoue, D. Aud, T. McNeil, S. Azuma, S. 
Yoshida, Y. Toyoda and K. Arai (1995). "Mice deficient for the IL-3/GM-CSF/IL-5 beta c 
receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-
deficient mice are normal." Immunity 2(3): 211-222. 
Odai, H., K. Sasaki, A. Iwamatsu, Y. Hanazono, T. Tanaka, K. Mitani, Y. Yazaki and H. Hirai 
(1995). "The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation 
with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human 





Olivares, R., P. Ducimetière and J. Claude (1993). "Monocyte count: a risk factor for coronary 
heart disease?" American journal of epidemiology 137(1): 49-53. 
Perry, H., T. Bender and C. McNamara (2012). "B cell subsets in atherosclerosis." Frontiers in 
immunology 3: 373. 
Rajavashisth, T., J. H. Qiao, S. Tripathi, J. Tripathi, N. Mishra, M. Hua, X. P. Wang, A. 
Loussararian, S. Clinton, P. Libby and A. Lusis (1998). "Heterozygous osteopetrotic (op) 
mutation reduces atherosclerosis in LDL receptor- deficient mice." J Clin Invest 101(12): 2702-
2710. 
Rauch, P. J., A. Chudnovskiy, C. S. Robbins, G. F. Weber, M. Etzrodt, I. Hilgendorf, E. Tiglao, 
J.-L. Figueiredo, Y. Iwamoto and I. Theurl (2012). "Innate response activator B cells protect 
against microbial sepsis." Science Signaling 335(6068): 597. 
Rauch, P. J., A. Chudnovskiy, C. S. Robbins, G. F. Weber, M. Etzrodt, I. Hilgendorf, E. Tiglao, J. 
L. Figueiredo, Y. Iwamoto, I. Theurl, R. Gorbatov, M. T. Waring, A. T. Chicoine, M. Mouded, 
M. J. Pittet, M. Nahrendorf, R. Weissleder and F. K. Swirski (2012). "Innate response activator 
B cells protect against microbial sepsis." Science 335(6068): 597-601. 
Robb, L. (2007). "Cytokine receptors and hematopoietic differentiation." Oncogene 26(47): 
6715-6723. 
Robbins, C. S., A. Chudnovskiy, P. J. Rauch, J. L. Figueiredo, Y. Iwamoto, R. Gorbatov, M. 
Etzrodt, G. F. Weber, T. Ueno, N. van Rooijen, M. J. Mulligan-Kehoe, P. Libby, M. Nahrendorf, 
M. J. Pittet, R. Weissleder and F. K. Swirski (2012). "Extramedullary hematopoiesis generates 
Ly-6C(high) monocytes that infiltrate atherosclerotic lesions." Circulation 125(2): 364-374. 
Roger, V., A. Go, D. Lloyd-Jones, E. Benjamin, J. Berry, W. Borden, D. Bravata, S. Dai, E. Ford, 
C. Fox, H. Fullerton, C. Gillespie, S. Hailpern, J. Heit, V. Howard, B. Kissela, S. Kittner, D. 
Lackland, J. Lichtman, L. Lisabeth, D. Makuc, G. Marcus, A. Marelli, D. Matchar, C. Moy, D. 
Mozaffarian, M. Mussolino, G. Nichol, N. Paynter, E. Soliman, P. Sorlie, N. Sotoodehnia, T. 
Turan, S. Virani, N. Wong, D. Woo, M. Turner, C. American Heart Association Statistics and S. 
Stroke Statistics (2012). "Executive summary: heart disease and stroke statistics--2012 update: a 
report from the American Heart Association." Circulation 125(1): 188-197. 
Rudolph, T., K.-P. Schaps, D. Steven, R. Koester, V. Rudolph, J. Berger, W. Terres, T. Meinertz 
and J. Kaehler (2009). "Interleukin-3 is elevated in patients with coronary artery disease and 
predicts restenosis after percutaneous coronary intervention." International journal of cardiology 
132(3): 392-397. 
Rust, S., M. Rosier, H. Funke, J. Real, Z. Amoura, J. Piette, J. Deleuze, H. Brewer, N. Duverger, 
P. Denèfle and G. Assmann (1999). "Tangier disease is caused by mutations in the gene 
encoding ATP-binding cassette transporter 1." Nature genetics 22(4): 352-355. 
Saederup, N., L. Chan, S. Lira and I. Charo (2008). "Fractalkine deficiency markedly reduces 
macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for 
independent chemokine functions in atherogenesis." Circulation 117(13): 1642-1648. 
Sage, A., D. Tsiantoulas, L. Baker, J. Harrison, L. Masters, D. Murphy, C. Loinard, C. Binder 
and Z. Mallat (2012). "BAFF receptor deficiency reduces the development of atherosclerosis in 





Sakamaki, K., I. Miyajima, T. Kitamura and A. Miyajima (1992). "Critical cytoplasmic domains 
of the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors for growth signal 
transduction and tyrosine phosphorylation." The EMBO journal 11(10): 3541-3549. 
Salgia, R., T. Lynch, A. Skarin, J. Lucca, C. Lynch, K. Jung, F. Hodi, M. Jaklitsch, S. Mentzer, S. 
Swanson, J. Lukanich, R. Bueno, J. Wain, D. Mathisen, C. Wright, P. Fidias, D. Donahue, S. 
Clift, S. Hardy, D. Neuberg, R. Mulligan, I. Webb, D. Sugarbaker, M. Mihm and G. Dranoff 
(2003). "Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-
macrophage colony-stimulating factor augments antitumor immunity in some patients with 
metastatic non-small-cell lung carcinoma." Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 21(4): 624-630. 
Sallusto, F. and A. Lanzavecchia (1994). "Efficient presentation of soluble antigen by cultured 
human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus 
interleukin 4 and downregulated by tumor necrosis factor alpha." The Journal of experimental 
medicine 179(4): 1109-1118. 
Scott, C. and C. Begley (1999). "The beta common chain (beta c) of the granulocyte 
macrophage-colony stimulating factor, interleukin-3 and interleukin-5 receptors." The 
international journal of biochemistry & cell biology 31(10): 1011-1015. 
Seimon, T. and I. Tabas (2009). "Mechanisms and consequences of macrophage apoptosis in 
atherosclerosis." Journal of lipid research 50 Suppl: 7. 
Shaposhnik, Z., X. Wang, M. Weinstein, B. Bennett and A. Lusis (2007). "Granulocyte 
macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions." 
Arteriosclerosis, thrombosis, and vascular biology 27(3): 621-627. 
Shaposhnik, Z., X. Wang, M. Weinstein, B. J. Bennett and A. J. Lusis (2007). "Granulocyte 
macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions." 
Arterioscler Thromb Vasc Biol 27(3): 621-627. 
Shindo, J., T. Ishibashi, K. Yokoyama, K. Nakazato, T. Ohwada, M. Shiomi and Y. Maruyama 
(1999). "Granulocyte-macrophage colony-stimulating factor prevents the progression of 
atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic 
lesions in watanabe heritable hyperlipidemic rabbits." Circulation 99(16): 2150-2156. 
Shortman, K. and S. Naik (2007). "Steady-state and inflammatory dendritic-cell development." 
Nature reviews. Immunology 7(1): 19-30. 
Smith, J. D., E. Trogan, M. Ginsberg, C. Grigaux, J. Tian and M. Miyata (1995). "Decreased 
atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and 
apolipoprotein E." Proceedings of the National Academy of Sciences 92(18): 8264-8268. 
Soehnlein, O., M. Drechsler, Y. Döring, D. Lievens, H. Hartwig, K. Kemmerich, A. Ortega-
Gómez, M. Mandl, S. Vijayan, D. Projahn, C. Garlichs, R. Koenen, M. Hristov, E. Lutgens, A. 
Zernecke and C. Weber (2013). "Distinct functions of chemokine receptor axes in the 
atherogenic mobilization and recruitment of classical monocytes." EMBO molecular medicine 
5(3): 471-481. 
Soehnlein, O. and L. Lindbom (2010). "Phagocyte partnership during the onset and resolution of 





Soehnlein, O. and F. K. Swirski (2012). "Hypercholesterolemia links hematopoiesis with 
atherosclerosis." Trends Endocrinol Metab. 
Soiffer, R., F. Hodi, F. Haluska, K. Jung, S. Gillessen, S. Singer, K. Tanabe, R. Duda, S. 
Mentzer, M. Jaklitsch, R. Bueno, S. Clift, S. Hardy, D. Neuberg, R. Mulligan, I. Webb, M. Mihm 
and G. Dranoff (2003). "Vaccination with irradiated, autologous melanoma cells engineered to 
secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer 
augments antitumor immunity in patients with metastatic melanoma." Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 21(17): 3343-3350. 
Stanley, E., G. Lieschke, D. Grail, D. Metcalf, G. Hodgson, J. Gall, D. Maher, J. Cebon, V. 
Sinickas and A. Dunn (1994). "Granulocyte/macrophage colony-stimulating factor-deficient 
mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary 
pathology." Proceedings of the National Academy of Sciences of the United States of America 
91(12): 5592-5596. 
Stoneman, V., D. Braganza, N. Figg, J. Mercer, R. Lang, M. Goddard and M. Bennett (2007). 
"Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice 
differentially affects atherogenesis and established plaques." Circulation research 100(6): 884-
893. 
Subramanian, M., E. Thorp, G. Hansson and I. Tabas (2013). "Treg-mediated suppression of 
atherosclerosis requires MYD88 signaling in DCs." The Journal of clinical investigation 123(1): 
179-188. 
Subramanian, M., E. Thorp, G. K. Hansson and I. Tabas (2013). "Treg-mediated suppression of 
atherosclerosis requires MYD88 signaling in DCs." The Journal of Clinical Investigation 123(1): 
179-188. 
Suda, T., J. Suda, M. Ogawa and J. Ihle (1985). "Permissive role of interleukin 3 (IL-3) in 
proliferation and differentiation of multipotential hemopoietic progenitors in culture." Journal of 
cellular physiology 124(2): 182-190. 
Sweetnam, P., H. Thomas, J. Yarnell, I. Baker and P. Elwood (1997). "Total and differential 
leukocyte counts as predictors of ischemic heart disease: the Caerphilly and Speedwell studies." 
American journal of epidemiology 145(5): 416-421. 
Sweetnam, P. M., H. F. Thomas, J. W. G. Yarnell, I. A. Baker and P. C. Elwood (1997). "Total 
and differential leukocyte counts as predictors of ischemic heart disease: The Caerphilly and 
Speedwell studies." American Journal of Epidemiology 145(5): 416-421. 
Swirski, F. and C. Robbins (2013). "Neutrophils usher monocytes into sites of inflammation." 
Circulation research 112(5): 744-745. 
Swirski, F. K., P. Libby, E. Aikawa, P. Alcaide, F. W. Luscinskas, R. Weissleder and M. J. Pittet 
(2007). "Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give 
rise to macrophages in atheromata." The Journal of Clinical Investigation 117(1): 195-205. 
Swirski, F. K., M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo, P. Panizzi, J. L. 
Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, E. Aikawa, T. R. Mempel, P. Libby, R. 
Weissleder and M. J. Pittet (2009). "Identification of Splenic Reservoir Monocytes and Their 





Tabas, I. (2010). "Macrophage death and defective inflammation resolution in atherosclerosis." 
Nature reviews. Immunology 10(1): 36-46. 
Tacke, F., D. Alvarez, T. J. Kaplan, C. Jakubzick, R. Spanbroek, J. Llodra, A. Garin, J. Liu, M. 
Mack, N. van Rooijen, S. A. Lira, A. J. Habenicht and G. J. Randolph (2007). "Monocyte subsets 
differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques." 
J Clin Invest 117(1): 185-194. 
Takeda, M., T. Yamashita, N. Sasaki, K. Nakajima, T. Kita, M. Shinohara, T. Ishida and K. 
Hirata (2010). "Oral administration of an active form of vitamin D3 (calcitriol) decreases 
atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with 
tolerogenic functions." Arterioscler Thromb Vasc Biol 30(12): 2495-2503. 
Tall, A., L. Yvan-Charvet, N. Terasaka, T. Pagler and N. Wang (2008). "HDL, ABC transporters, 
and cholesterol efflux: implications for the treatment of atherosclerosis." Cell metabolism 7(5): 
365-375. 
Tall, A. R., L. Yvan-Charvet, M. Westerterp and A. J. Murphy (2012). "Cholesterol efflux: a 
novel regulator of myelopoiesis and atherogenesis." Arterioscler Thromb Vasc Biol 32(11): 
2547-2552. 
Tani, S., K. Nagao, T. Anazawa, H. Kawamata, S. Furuya, H. Takahashi, K. Iida, M. Matsumoto, 
T. Washio, N. Kumabe and A. Hirayama (2009). "Association of leukocyte subtype counts with 
coronary atherosclerotic regression following pravastatin treatment." The American journal of 
cardiology 104(4): 464-469. 
Tarling, E., D. Bojanic, R. Tangirala, X. Wang, A. Lovgren-Sandblom, A. Lusis, I. Bjorkhem 
and P. Edwards (2010). "Impaired development of atherosclerosis in Abcg1-/- Apoe-/- mice: 
identification of specific oxysterols that both accumulate in Abcg1-/- Apoe-/- tissues and induce 
apoptosis." Arteriosclerosis, thrombosis, and vascular biology 30(6): 1174-1180. 
Terasaka, N., N. Wang, L. Yvan-Charvet and A. Tall (2007). "High-density lipoprotein protects 
macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-
ketocholesterol via ABCG1." Proceedings of the National Academy of Sciences of the United 
States of America 104(38): 15093-15098. 
Thomassen, M., B. Barna, A. Malur, T. Bonfield, C. Farver, A. Malur, H. Dalrymple, M. Kavuru 
and M. Febbraio (2007). "ABCG1 is deficient in alveolar macrophages of GM-CSF knockout 
mice and patients with pulmonary alveolar proteinosis." Journal of lipid research 48(12): 2762-
2768. 
Torigoe, T., R. O'Connor, D. Santoli and J. Reed (1992). "Interleukin-3 regulates the activity of 
the LYN protein-tyrosine kinase in myeloid-committed leukemic cell lines." Blood 80(3): 617-
624. 
Vallance, B., K. Matthaei, S. Sanovic, I. Young and S. Collins (2000). "Interleukin-5 deficient 
mice exhibit impaired host defence against challenge Trichinella spiralis infections." Parasite 
immunology 22(10): 487-492. 
Westerterp, M., S. Gourion-Arsiquaud, A. Murphy, A. Shih, S. Cremers, R. Levine, A. Tall and 
L. Yvan-Charvet (2012). "Regulation of hematopoietic stem and progenitor cell mobilization by 





Westerterp, M., S. Gourion-Arsiquaud, A. J. Murphy, A. Shih, S. Cremers, R. L. Levine, A. R. 
Tall and L. Yvan-Charvet (2012). "Regulation of hematopoietic stem and progenitor cell 
mobilization by cholesterol efflux pathways." Cell Stem Cell 11(2): 195-206. 
Westerterp, M., A. J. Murphy, M. Wang, T. A. Pagler, Y. Vengrenyuk, M. S. Kappus, D. J. 
Gorman, P. R. Nagareddy, X. Zhu, S. Abramowicz, J. S. Parks, C. L. Welch, E. A. Fisher, N. 
Wang, L. Yvan-Charvet and A. R. Tall (2013). "Deficiency of ABCA1 and ABCG1 in 
Macrophages Increases Inflammation and Accelerates Atherosclerosis in Mice." Circulation 
Research. 
Williams, K. and I. Tabas (1995). "The response-to-retention hypothesis of early atherogenesis." 
Arteriosclerosis, thrombosis, and vascular biology 15(5): 551-561. 
Williamson, D., C. Begley, M. Vadas and D. Metcalf (1988). "The detection and initial 
characterization of colony-stimulating factors in synovial fluid." Clinical and experimental 
immunology 72(1): 67-73. 
Wright, D. E., A. J. Wagers, A. P. Gulati, F. L. Johnson and I. L. Weissman (2001). 
"Physiological migration of hematopoietic stem and progenitor cells." Science 294(5548): 1933-
1936. 
Xiao, W., H. Hong, Y. Kawakami, C. Lowell and T. Kawakami (2008). "Regulation of 
myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5." 
The Journal of clinical investigation 118(3): 924-934. 
Ylitalo, R., J. Kalliovalkama, X. Wu, H. Kankaanranta, J. Salenius, T. Sisto, T. Lähteenmäki, P. 
Ylitalo and I. Pörsti (1998). "Accumulation of bisphosphonates in human artery and their effects 
on human and rat arterial function in vitro." Pharmacology & toxicology 83(3): 125-131. 
Yuan, H.-X., Y. Xiong and K.-L. Guan (2013). "Nutrient sensing, metabolism, and cell growth 
control." Molecular cell 49(3): 379-387. 
Yvan-Charvet, L., T. Pagler, E. Gautier, S. Avagyan, R. Siry, S. Han, C. Welch, N. Wang, G. 
Randolph, H. Snoeck and A. Tall (2010). "ATP-binding cassette transporters and HDL suppress 
hematopoietic stem cell proliferation." Science (New York, N.Y.) 328(5986): 1689-1693. 
Yvan-Charvet, L., T. Pagler, E. L. Gautier, S. Avagyan, R. L. Siry, S. Han, C. L. Welch, N. 
Wang, G. J. Randolph, H. W. Snoeck and A. R. Tall (2010). "ATP-Binding Cassette 
Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation." Science 328(5986): 
1689-1693. 
Yvan-Charvet, L., T. Pagler, T. Seimon, E. Thorp, C. Welch, J. Witztum, I. Tabas and A. Tall 
(2010). "ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis 
during efferocytosis." Circulation research 106(12): 1861-1869. 
Yvan-Charvet, L., M. Ranalletta, N. Wang, S. Han, N. Terasaka, R. Li, C. Welch and A. Tall 
(2007). "Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and 
accelerates atherosclerosis in mice." The Journal of clinical investigation 117(12): 3900-3908. 
Yvan-Charvet, L., C. Welch, T. Pagler, M. Ranalletta, M. Lamkanfi, S. Han, M. Ishibashi, R. Li, 
N. Wang and A. Tall (2008). "Increased inflammatory gene expression in ABC transporter-
deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, 





Zhang, S., R. Reddick, J. Piedrahita and N. Maeda (1992). "Spontaneous hypercholesterolemia 
and arterial lesions in mice lacking apolipoprotein E." Science (New York, N.Y.) 258(5081): 
468-471. 
Zheng, X., A. Karsan, V. Duronio, F. Chu, D. Walker, T. Bai and R. Schellenberg (2002). 
"Interleukin-3, but not granulocyte-macrophage colony-stimulating factor and interleukin-5, 
inhibits apoptosis of human basophils through phosphatidylinositol 3-kinase: requirement of NF-
kappaB-dependent and -independent pathways." Immunology 107(3): 306-315. 
Zhu, S.-N., M. Chen, J. Jongstra-Bilen and M. Cybulsky (2009). "GM-CSF regulates intimal cell 
proliferation in nascent atherosclerotic lesions." The Journal of experimental medicine 206(10): 
2141-2149. 
Zhu, S. N., M. Chen, J. Jongstra-Bilen and M. I. Cybulsky (2009). "GM-CSF regulates intimal 
cell proliferation in nascent atherosclerotic lesions." J Exp Med 206(10): 2141-2149. 
Zhu, X., J.-Y. Lee, J. Timmins, J. Brown, E. Boudyguina, A. Mulya, A. Gebre, M. Willingham, 
E. Hiltbold, N. Mishra, N. Maeda and J. Parks (2008). "Increased cellular free cholesterol in 
macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of 


















 bone marrow transplanted mice 






 (LSK) HSPC, GMP, CMP 
and MEP. Single cells were selected based on cell surface lineage markers, and Lin- cells were 






 progenitor cells were 
















loFcγRII/IIIlo, respectively.  
